Reference ID: 3847805: Interaction

HIGHLIGHTS OF PRESCRIBING INFORMATION •
Noxafil oral suspension 40 mg per mL (3)

These highlights do not include all the information needed to use
NOXAFIL safely and effectively. See full prescribing information -------------------------------CONTRAINDICATIONS------------------------------
for NOXAFIL. • Do not administer to persons with known hypersensitivity to
posaconazole or other azole antifungal agents. (4.1)
Noxafil® (posaconazole) injection 18 mg/mL • Do not coadminister Noxafil with the following drugs; Noxafil
Noxafil® (posaconazole) delayed-release tablets 100 mg increases concentrations of:
Noxafil® (posaconazole) oral suspension 40 mg/mL o Sirolimus: can result in sirolimus toxicity (4.2, 7.1)
Initial U.S. Approval: 2006 (oral suspension) o CYP3A4 substrates (pimozide, quinidine): can result in QTc
interval prolongation and cases of TdP (4.3, 7.2)
---------------------------RECENT MAJOR CHANGES -------------------------- o HMG-CoA Reductase Inhibitors Primarily Metabolized
Dosage and Administration (2) 11/2015 Through CYP3A4: can lead to rhabdomyolysis (4.4, 7.3)
o Ergot alkaloids: can result in ergotism (4.5, 7.4)
----------------------------INDICATIONS AND USAGE ----------------------------
Noxafil is an azole antifungal agent indicated for: ----------------------- WARNINGS AND PRECAUTIONS ----------------------
injection, delayed-release tablets, and oral suspension • Calcineurin Inhibitor Toxicity: Noxafil increases concentrations of
• prophylaxis of invasive Aspergillus and Candida infections in cyclosporine or tacrolimus; reduce dose of cyclosporine and
patients who are at high risk of developing these infections due to tacrolimus and monitor concentrations frequently. (5.1)
being severely immunocompromised, such as HSCT recipients with • Arrhythmias and QTc Prolongation: Noxafil has been shown to
GVHD or those with hematologic malignancies with prolonged prolong the QTc interval and cause cases of TdP. Administer with
neutropenia from chemotherapy. (1.1) caution to patients with potentially proarrhythmic conditions. Do not
Oral suspension administer with drugs known to prolong QTc interval and
• treatment of oropharyngeal candidiasis (OPC), including OPC metabolized through CYP3A4. Correct K+, Mg++, and Ca++ before
refractory (rOPC) to itraconazole and/or fluconazole. (1.2) starting Noxafil. (5.2)
• Hepatic Toxicity: Elevations in LFTs may occur. Discontinuation
----------------------- DOSAGE AND ADMINISTRATION ----------------------- should be considered in patients who develop abnormal LFTs or
monitor LFTs during treatment. (5.3)
Noxafil delayed-release tablets and oral suspension are not • Noxafil injection should be avoided in patients with moderate or
interchangeable due to the differences in the dosing of each severe renal impairment (creatinine clearance <50 mL/min), unless
formulation. Therefore, follow the specific dosage recommendations for an assessment of the benefit/risk to the patient justifies the use of
each of the formulations. (2.3, 2.4) Noxafil injection. (5.4, 8.6)
Indication Dose and Duration of Therapy • Midazolam: Noxafil can prolong hypnotic/sedative effects. Monitor
Prophylaxis of Injection*: patients and benzodiazepine receptor antagonists should be
invasive Loading dose: 300 mg Noxafil injection available. (5.5, 7.5)
Aspergillus and intravenously twice a day on the first day.
Candida Maintenance dose: 300 mg Noxafil injection ------------------------------ ADVERSE REACTIONS -----------------------------
infections intravenously once a day thereafter. Duration of • Common treatment-emergent adverse reactions in studies with
therapy is based on recovery from neutropenia posaconazole are diarrhea, nausea, fever, vomiting, headache,
or immunosuppression. (2.1) coughing, and hypokalemia. (6.2)
Delayed-Release Tablets†: To report SUSPECTED ADVERSE REACTIONS, contact Merck
Loading dose: 300 mg (three 100 mg Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., at 1-877
delayed-release tablets) twice a day on the first 888-4231 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
day.
Maintenance dose: 300 mg (three 100 mg -------------------------------DRUG INTERACTIONS------------------------------
delayed-release tablets) once a day, starting on
the second day. Duration of therapy is based Interaction Drug Interaction
on recovery from neutropenia or Rifabutin, phenytoin, efavirenz, Avoid coadministration unless
immunosuppression. (2.2) cimetidine, esomeprazole* the benefit outweighs the risks
Oral Suspension‡: 200 mg (5 mL) three times (7.6, 7.7, 7.8, 7.9)
a day. Duration of therapy is based on recovery Other drugs metabolized by Consider dosage adjustment
from neutropenia or immunosuppression. (2.3) CYP3A4 and monitor for adverse effects
Oropharyngeal Oral Suspension‡: and toxicity (7.1, 7.10, 7.11)
Candidiasis Loading dose: 100 mg (2.5 mL) twice a day on Digoxin Monitor digoxin plasma
(OPC) the first day. concentrations (7.12)
Maintenance dose: 100 mg (2.5 mL) once a Fosamprenavir, Monitor for breakthrough fungal
day for 13 days. (2.3) metoclopramide* infections (7.6, 7.13)
OPC Refractory Oral Suspension‡: 400 mg (10 mL) twice a *The drug interactions with esomeprazole and metoclopramide do
(rOPC) to day. Duration of therapy is based on the not apply to posaconazole tablets.
Itraconazole severity of the patient’s underlying disease and
and/or clinical response. (2.3) ----------------------- USE IN SPECIFIC POPULATIONS ----------------------
Fluconazole • Pregnancy: Based on animal data, may cause fetal harm. (8.1)
*Noxafil injection must be administered through an in-line filter. • Nursing Mothers: Discontinue drug or nursing, taking in to
Administer by intravenous infusion over approximately 90 minutes via consideration the importance of drug to the mother. (8.3)
a central venous line. Never give Noxafil injection as an intravenous • Severe renal impairment: Monitor closely for breakthrough fungal
bolus injection. (2) infections. (8.6)
†
Noxafil delayed-release tablets should be taken with food. (2)
‡
Noxafil oral suspension should be taken with a full meal. (2) See 17 for PATIENT COUNSELING INFORMATION and FDA-
approved patient labeling.
Revised: 11/2015
--------------------- DOSAGE FORMS AND STRENGTHS --------------------
• Noxafil injection: 300 mg per 16.7 mL (18 mg per mL) (3)
• Noxafil delayed-release tablet 100 mg (3)
Reference ID: 3847805

FULL PRESCRIBING INFORMATION: CONTENTS* 7.6 Anti-HIV Drugs
7.7 Rifabutin
1 INDICATIONS AND USAGE 7.8 Phenytoin
1.1 Prophylaxis of Invasive Aspergillus and Candida Infections 7.9 Gastric Acid Suppressors/Neutralizers
1.2 Treatment of Oropharyngeal Candidiasis Including 7.10 Vinca A kaloids
Oropharyngeal Candidiasis Refractory to Itraconazole and/or 7.11 Calcium Channel Blockers Metabolized by CYP3A4
Fluconazole 7.12 Digoxin
2 DOSAGE AND ADMINISTRATION 7.13 Gastrointestinal Motility Agents
2.1 Important Administration Instructions for Noxafil Injection, 7.14 Glipizide
Noxafil Delayed-Release Tablets and Noxafil Oral 8 USE IN SPECIFIC POPULATIONS
Suspension 8.1 Pregnancy
2.2 Dosage, Preparation, Intravenous Line Compatibility and 8.3 Nursing Mothers
Administration of Noxafil Injection 8.4 Pediatric Use
2.3 Dosage and Administration Instructions for Noxafil Delayed- 8.5 Geriatric Use
Release Tablets 8.6 Renal Impairment
2.4 Dosage and Administration Instructions for Noxafil Oral 8.7 Hepatic Impairment
Suspension 8.8 Gender
2. 5 Non-Interchangeability between Noxafil Delayed-Release 8.9 Race
Tablets and Noxafil Oral Suspension 8.10 Weight
2.6 Dosage Adjustments in Patients with Renal Impairment 10 OVERDOSAGE
3 DOSAGE FORMS AND STRENGTHS 11 DESCRIPTION
4 CONTRAINDICATIONS 12 CLINICAL PHARMACOLOGY
4.1 Hypersensitivity 12.1 Mechanism of Action
4.2 Use with Sirolimus 12.2 Pharmacodynamics
4.3 QT Prolongation with Concomitant Use with CYP3A4
12.3 Pharmacokinetics
Substrates
12.4 Microbiology
4.4 HMG-CoA Reductase Inhibitors Primarily Metabolized 13 NONCLINICAL TOXICOLOGY
Through CYP3A4 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility
4.5 Use with Ergot A kaloids 13.2 Animal Toxicology and/or Pharmacology
5 WARNINGS AND PRECAUTIONS 14 CLINICAL STUDIES
5.1 Calcineurin-Inhibitor Drug Interactions 14.1 Prophylaxis of Aspergillus and Candida Infections with
5.2 Arrhythmias and QT Prolongation Posaconazole Oral Suspension
5.3 Hepatic Toxicity 14.2 Treatment of Oropharyngeal Candidiasis with Posaconazole
5.4 Renal Impairment Oral Suspension
5.5 Use with Midazolam 14.3 Posaconazole Oral Suspension Treatment of Oropharyngeal
6 ADVERSE REACTIONS Candidiasis Refractory to Treatment with Fluconazole or
6.1 Serious and Otherwise Important Adverse Reactions Itraconazole
6.2 Clinical Trials Experience 16 HOW SUPPLIED/STORAGE AND HANDLING
6.3 Postmarketing Experience 17 PATIENT COUNSELING INFORMATION
7 DRUG INTERACTIONS 17.1 Administration
7.1 Immunosuppressants Metabolized by CYP3A4 17.2 Drug Interactions
7.2 CYP3A4 Substrates 17.3 Serious and Potentially Serious Adverse Reactions
7.3 HMG-CoA Reductase Inhibitors (Statins) Primarily
Metabolized Through CYP3A4

*Sections or subsections omitted from the full prescr bing information
7.4 Ergot A kaloids are not listed.
7.5 Benzodiazepines Metabolized by CYP3A4
FULL PRESCRIBING INFORMATION
1 INDICATIONS AND USAGE

1.1 Prophylaxis of Invasive Aspergillus and Candida Infections
®
Noxafil injection, delayed-release tablets, and oral suspension are indicated for prophylaxis of
invasive Aspergillus and Candida infections in patients who are at high risk of developing these infections
due to being severely immunocompromised, such as hematopoietic stem cell transplant (HSCT)
recipients with graft-versus-host disease (GVHD) or those with hematologic malignancies with prolonged
neutropenia from chemotherapy.
Noxafil injection is indicated in patients 18 years of age and older.
Noxafil delayed-release tablets and oral suspension are indicated in patients 13 years of age and
older.
1.2 Treatment of Oropharyngeal Candidiasis Including Oropharyngeal Candidiasis Refractory

to Itraconazole and/or Fluconazole
Noxafil oral suspension is indicated for the treatment of oropharyngeal candidiasis, including
oropharyngeal candidiasis refractory to itraconazole and/or fluconazole.

2 DOSAGE AND ADMINISTRATION
2.1 Important Administration Instructions for Noxafil Injection, Noxafil Delayed-Release Tablets
and Noxafil Oral Suspension
Noxafil delayed-release tablets and oral suspension are not to be used interchangeably due to the
differences in the dosing of each formulation [see Dosage and Administration (2.3, 2.4, 2.5)].
Noxafil injection
• Administer via a central venous line, including a central venous catheter or peripherally inserted
central catheter (PICC), by slow intravenous infusion over approximately 90 minutes [see Dosage
and Administration (2.2)].
• If a central venous catheter is not available, Noxafil injection may be administered through a
peripheral venous catheter by slow intravenous infusion over 30 minutes only as a single dose in
advance of central venous line placement or to bridge the period during which a central venous line is
replaced or is in use for other intravenous treatment.
• When multiple dosing is required, the infusion should be done via a central venous line.
• Never administer Noxafil injection as an intravenous bolus injection.
Noxafil delayed-release tablets
• Swallow tablets whole. Do not divide, crush, or chew.
• Administer with food [see Dosage and Administration (2.3) and Clinical Pharmacology (12.3)].
Noxafil oral suspension
• Administer with a full meal or with a liquid nutritional supplement or an acidic carbonated beverage
(e.g., ginger ale) in patients who cannot eat a full meal [see Dosage and Administration (2.4)]
• Co-administration of drugs that can decrease the plasma concentrations of posaconazole should
generally be avoided unless the benefit outweighs the risk. If such drugs are necessary, patients
should be monitored closely for breakthrough fungal infections [see Drug Interactions (7.6, 7.7, 7.8,
7.9, 7.13)]
Noxafil delayed-release tablets and Noxafil oral suspension

• Patients who have severe diarrhea or vomiting should be monitored closely for breakthrough fungal
infections when receiving Noxafil delayed-release tablets or oral suspension.
2.2 Dosage, Preparation, Intravenous Line Compatibility and Administration of Noxafil

Injection
Dosage:
Table 1: Dosage for Noxafil Injection

Indication Dose and Duration of Therapy
Loading dose:
Prophylaxis of invasive Aspergillus 300 mg Noxafil injection intravenously twice a day on the
and Candida infections first day.
Maintenance dose:
300 mg Noxafil injection intravenously once a day, starting
on the second day. Duration of therapy is based on recovery
from neutropenia or immunosuppression.
Preparation:
• Equilibrate the refrigerated vial of Noxafil (posaconazole) injection to room temperature.

• To prepare the required dose, aseptically transfer one vial (16.7 mL) of Noxafil injection (containing
300 mg of posaconazole in solution) to an intravenous bag (or bottle) of a compatible admixture

diluent (as described in Table 2), to achieve a final concentration of posaconazole that is between 1
mg/mL and 2 mg/mL. Use of other diluents is not recommended because they may result in
particulate formation.
• Noxafil injection is a single dose sterile solution without preservatives. Once admixed, the product
should be used immediately. If not used immediately, the solution can be stored up to 24 hours
refrigerated 2-8°C (36-46°F). Noxafil injection is for single use only and any unused solution should
be discarded.
• Parenteral drug products should be inspected visually for particulate matter prior to administration,
whenever solution and container permit. Once admixed, the solution of Noxafil ranges from colorless
to yellow. Variations of color within this range do not affect the quality of the product.
Intravenous Line Compatibility:
A study was conducted to evaluate physical compatibility of Noxafil injection with injectable drug products
and commonly used intravenous diluents during simulated Y-site infusion. Compatibility was determined
through visual observations, measurement of particulate matter and turbidity. Compatible diluents and
drug products are listed in Tables 2 and 3 below. Any diluents or drug products not listed in the tables
below should not be co-administered through the same intravenous line (or cannula).
• Noxafil injection can be infused at the same time through the same intravenous line (or cannula) with
the following compatible diluents:
Table 2: Compatible Diluents

0.45% sodium chloride
0.9% sodium chloride
5% dextrose in water
5% dextrose and 0.45% sodium chloride
5% dextrose and 0.9% sodium chloride
5% dextrose and 20 mEq potassium chloride
• Noxafil injection can be infused at the same time through the same intravenous line (or cannula) with
the following drug products prepared in 5% dextrose in water or sodium chloride 0.9%. Co-
administration of drug products prepared in other diluents may result in particulate formation.
Table 3: Compatible Drugs

Amikacin sulfate
Caspofungin
Ciprofloxacin
Daptomycin
Dobutamine hydrochloride
Famotidine
Filgrastim
Gentamicin sulfate
Hydromorphone hydrochloride
Levofloxacin
Lorazepam
Meropenem
Micafungin
Morphine sulfate
Norepinephrine bitartrate
Potassium chloride
Vancomycin hydrochloride
Incompatible Diluents:

Noxafil injection must not be diluted with the following diluents:
Lactated Ringer’s solution

5% dextrose with Lactated Ringer’s solution
4.2% sodium bicarbonate
Administration:
• Noxafil injection must be administered through a 0.22 micron polyethersulfone (PES) or

polyvinylidene difluoride (PVDF) filter.
• Administer via a central venous line, including a central venous catheter or PICC by slow infusion
over approximately 90 minutes. Noxafil injection is not for bolus administration.
• If a central venous catheter is not available, Noxafil injection may be administered through a
peripheral venous catheter only as a single dose in advance of central venous line placement or to
bridge the period during which a central venous line is replaced or is in use for other treatment.
• When multiple dosing is required, the infusion should be done via a central venous line. When
administered through a peripheral venous catheter, the infusion should be administered over
approximately 30 minutes. Note: In clinical trials, multiple peripheral infusions given through the same
vein resulted in infusion site reactions [see Adverse Reactions (6.2)].
2.3 Dosage and Administration Instructions for Noxafil Delayed-Release Tablets

Dosage:
Table 4: Dosage for Noxafil Delayed-Release Tablets

Prophylaxis of invasive Aspergillus and Loading dose: 300 mg (three 100 mg delayed-release tablets) twice a
Candida infections day on the first day.
Maintenance dose: 300 mg (three 100 mg delayed-release tablets)

once a day, starting on the second day. Duration of therapy is based
on recovery from neutropenia or immunosuppression.
Administration Instructions for Noxafil Delayed-Release Tablets:
• Swallow tablets whole. Do not divide, crush, or chew.

• Administer Noxafil delayed-release tablets with food to enhance the oral absorption of posaconazole
and optimize plasma concentrations [see Clinical Pharmacology (12.3)].
• Noxafil delayed-release tablets should be used only for the prophylaxis indication.
• Noxafil delayed-release tablets generally provide higher plasma drug exposures than Noxafil oral
suspension under both fed and fasted conditions, and therefore is the preferred oral formulation for
the prophylaxis indication.
2.4 Dosage and Administration Instructions for Noxafil Oral Suspension
Dosage:
Table 5: Dosage for Noxafil Oral Suspension

Prophylaxis of invasive Aspergillus 200 mg (5 mL) three times a day. The duration of therapy is based on
and Candida infections recovery from neutropenia or immunosuppression.

Oropharyngeal Candidiasis Loading dose: 100 mg (2.5 mL) twice a day on the first day.
Maintenance dose: 100 mg (2.5 mL) once a day for 13 days.
Oropharyngeal Candidiasis Refractory 400 mg (10 mL) twice a day. Duration of therapy should be based on
to Itraconazole and/or Fluconazole the severity of the patient’s underlying disease and clinical response.
Administration Instructions for Noxafil Oral Suspension:

• Shake Noxafil oral suspension well before use. Administer with measured dosing spoon (see Figure
1) provided.
Figure 1: A measured dosing spoon is provided, marked for doses of 2.5 mL and 5 mL.
• Rinse the spoon with water after each administration and before storage.
• Administer each dose of Noxafil oral suspension during or immediately (i.e., within 20 minutes)
following a full meal to enhance the oral absorption of Noxafil and optimize plasma concentrations
[see Clinical Pharmacology (12.3)].
• For patients who cannot eat a full meal, Noxafil delayed-release tablets should be used instead of
Noxafil oral suspension. Noxafil delayed-release tablets should be used only for the prophylaxis
indication. Noxafil delayed-release tablets provide higher plasma drug exposures than Noxafil oral
suspension under fasted conditions [See Dosage and Administration (2.5)].
• In patients who cannot eat a full meal and for whom Noxafil delayed-release tablets or Noxafil
injection are not options, administer each dose of Noxafil oral suspension with a liquid nutritional
supplement or an acidic carbonated beverage (e.g., ginger ale).
• For patients who cannot eat a full meal or tolerate an oral nutritional supplement or an acidic
carbonated beverage and who do not have the option of taking Noxafil delayed-release tablets or
Noxafil injection, an alternative antifungal therapy should be considered or patients should be
monitored closely for breakthrough fungal infections.
2.5 Non-Interchangeability between Noxafil Delayed-Release Tablets and Noxafil Oral

Suspension
Noxafil delayed-release tablets and oral suspension are not to be used interchangeably due to the
differences in the dosing of each formulation. Therefore, follow the specific dosage recommendations for
each of the formulations [see Dosage and Administration (2.3, 2.4)].
2.6 Dosage Adjustments in Patients with Renal Impairment

The pharmacokinetics of Noxafil oral suspension and delayed-release tablets are not significantly
affected by renal impairment. Therefore, no adjustment is necessary for oral dosing in patients with mild
to severe renal impairment.
• Noxafil injection should be avoided in patients with moderate or severe renal impairment (eGFR <50
mL/min), unless an assessment of the benefit/risk to the patient justifies the use of Noxafil injection.
• In patients with moderate or severe renal impairment (estimated glomerular filtration rate (eGFR) <50
mL/min), receiving the Noxafil injection, accumulation of the intravenous vehicle, Betadex Sulfobutyl
Ether Sodium (SBECD), is expected to occur. Serum creatinine levels should be closely monitored in
these patients, and, if increases occur, consideration should be given to changing to oral Noxafil
therapy.

3 DOSAGE FORMS AND STRENGTHS
Noxafil injection is available in Type I glass vials closed with bromobutyl rubber stopper and aluminum
seal containing 300 mg per 16.7 mL of solution (18 mg of posaconazole per mL).
Noxafil 100 mg delayed-release tablets are available as yellow, coated, oblong tablets, debossed with
"100" on one side.
Noxafil oral suspension is available in 4-ounce (123 mL) amber glass bottles with child-resistant
closures containing 105 mL of suspension (40 mg of posaconazole per mL).
4 CONTRAINDICATIONS
4.1 Hypersensitivity
Noxafil is contraindicated in persons with known hypersensitivity to posaconazole or other azole
antifungal agents.
4.2 Use with Sirolimus
Noxafil is contraindicated with sirolimus. Concomitant administration of Noxafil with sirolimus increases
the sirolimus blood concentrations by approximately 9-fold and can result in sirolimus toxicity [see Drug
Interactions (7.1) and Clinical Pharmacology (12.3)].
4.3 QT Prolongation with Concomitant Use with CYP3A4 Substrates
Noxafil is contraindicated with CYP3A4 substrates that prolong the QT interval. Concomitant
administration of Noxafil with the CYP3A4 substrates, pimozide and quinidine may result in increased
plasma concentrations of these drugs, leading to QTc prolongation and cases of torsades de pointes [see
Warnings and Precautions (5.2) and Drug Interactions (7.2)].
4.4 HMG-CoA Reductase Inhibitors Primarily Metabolized Through CYP3A4
Coadministration with the HMG-CoA reductase inhibitors that are primarily metabolized through
CYP3A4 (e.g., atorvastatin, lovastatin, and simvastatin) is contraindicated since increased plasma
concentration of these drugs can lead to rhabdomyolysis [see Drug Interactions (7.3) and Clinical
Pharmacology (12.3)].
4.5 Use with Ergot Alkaloids
Posaconazole may increase the plasma concentrations of ergot alkaloids (ergotamine and
dihydroergotamine) which may lead to ergotism [see Drug Interactions (7.4)].
5 WARNINGS AND PRECAUTIONS

5.1 Calcineurin-Inhibitor Drug Interactions
Concomitant administration of Noxafil with cyclosporine or tacrolimus increases the whole blood
trough concentrations of these calcineurin-inhibitors [see Drug Interactions (7.1) and Clinical
Pharmacology (12.3)]. Nephrotoxicity and leukoencephalopathy (including deaths) have been reported in
clinical efficacy studies in patients with elevated cyclosporine or tacrolimus concentrations. Frequent
monitoring of tacrolimus or cyclosporine whole blood trough concentrations should be performed during
and at discontinuation of posaconazole treatment and the tacrolimus or cyclosporine dose adjusted
accordingly.
5.2 Arrhythmias and QT Prolongation
Some azoles, including posaconazole, have been associated with prolongation of the QT interval on
the electrocardiogram. In addition, cases of torsades de pointes have been reported in patients taking
posaconazole.
Results from a multiple time-matched ECG analysis in healthy volunteers did not show any increase in
the mean of the QTc interval. Multiple, time-matched ECGs collected over a 12-hour period were
recorded at baseline and steady-state from 173 healthy male and female volunteers (18-85 years of age)
administered posaconazole oral suspension 400 mg BID with a high-fat meal. In this pooled analysis, the
mean QTc (Fridericia) interval change from baseline was –5 msec following administration of the
recommended clinical dose. A decrease in the QTc(F) interval (–3 msec) was also observed in a small
number of subjects (n=16) administered placebo. The placebo-adjusted mean maximum QTc(F) interval
change from baseline was <0 msec (–8 msec). No healthy subject administered posaconazole had a
QTc(F) interval ≥500 msec or an increase ≥60 msec in their QTc(F) interval from baseline.

Posaconazole should be administered with caution to patients with potentially proarrhythmic
conditions. Do not administer with drugs that are known to prolong the QTc interval and are metabolized
through CYP3A4 [see Contraindications (4.3) and Drug Interactions (7.2)]. Rigorous attempts to correct
potassium, magnesium, and calcium should be made before starting posaconazole.
5.3 Hepatic Toxicity
Hepatic reactions (e.g., mild to moderate elevations in alanine aminotransferase (ALT), aspartate
aminotransferase (AST), alkaline phosphatase, total bilirubin, and/or clinical hepatitis) have been reported
in clinical trials. The elevations in liver function tests were generally reversible on discontinuation of
therapy, and in some instances these tests normalized without drug interruption. Cases of more severe
hepatic reactions including cholestasis or hepatic failure including deaths have been reported in patients
with serious underlying medical conditions (e.g., hematologic malignancy) during treatment with
posaconazole. These severe hepatic reactions were seen primarily in subjects receiving the
posaconazole oral suspension 800 mg daily (400 mg BID or 200 mg QID) in clinical trials.
Liver function tests should be evaluated at the start of and during the course of posaconazole therapy.
Patients who develop abnormal liver function tests during posaconazole therapy should be monitored for
the development of more severe hepatic injury. Patient management should include laboratory evaluation
of hepatic function (particularly liver function tests and bilirubin). Discontinuation of posaconazole must be
considered if clinical signs and symptoms consistent with liver disease develop that may be attributable to
posaconazole.
5.4 Renal Impairment
Due to the variability in exposure with Noxafil delayed-release tablets and oral suspension, patients
with severe renal impairment should be monitored closely for breakthrough fungal infections [see Dosage
and Administration (2.6) and Use in Specific Populations (8.6)].
Noxafil injection should be avoided in patients with moderate or severe renal impairment (eGFR <50
mL/min), unless an assessment of the benefit/risk to the patient justifies the use of Noxafil injection. In
patients with moderate or severe renal impairment (eGFR <50 mL/min), receiving the Noxafil injection,
accumulation of the intravenous vehicle, SBECD, is expected to occur. Serum creatinine levels should be
closely monitored in these patients, and, if increases occur, consideration should be given to changing to
oral Noxafil therapy [see Dosage and Administration (2.6) and Use in Specific Populations (8.6)].
5.5 Use with Midazolam
Concomitant administration of Noxafil with midazolam increases the midazolam plasma
concentrations by approximately 5-fold. Increased plasma midazolam concentrations could potentiate and
prolong hypnotic and sedative effects. Patients must be monitored closely for adverse effects associated
with high plasma concentrations of midazolam and benzodiazepine receptor antagonists must be
available to reverse these effects [see Drug Interactions (7.5) and Clinical Pharmacology (12.3)].
6 ADVERSE REACTIONS
6.1 Serious and Otherwise Important Adverse Reactions
The following serious and otherwise important adverse reactions are discussed in detail in another
section of the labeling:
• Hypersensitivity [see Contraindications (4.1)]
• Arrhythmias and QT Prolongation [see Warnings and Precautions (5.2)]
• Hepatic Toxicity [see Warnings and Precautions (5.3)]
6.2 Clinical Trials Experience
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed
in clinical trials of Noxafil cannot be directly compared to rates in the clinical trials of another drug and
may not reflect the rates observed in practice. In clinical trials, the type of adverse reactions reported for
posaconazole injection and posaconazole delayed-release tablets were generally similar to that reported
in trials of posaconazole oral suspension.
Clinical Trial Experience with Posaconazole Injection
Multiple doses of posaconazole injection administered via a peripheral venous catheter were
associated with thrombophlebitis (60% incidence). Therefore, in subsequent studies, posaconazole
injection was administered via central venous catheter.

The safety of posaconazole injection has been assessed in 268 patients in a clinical trial. Patients
were enrolled in a non-comparative pharmacokinetic and safety trial of posaconazole injection when
given as antifungal prophylaxis (Posaconazole Injection Study 1). Patients were immunocompromised
with underlying conditions including hematological malignancy, neutropenia post-chemotherapy, GVHD,
and post HSCT. This patient population was 55% male, had a mean age of 51 years (range 18-82 years,
19% of patients were ≥65 years of age), and were 95% white and 8% Hispanic. Ten patients received a
single dose of 200 mg posaconazole injection, 21 patients received 200 mg daily dose for a median of 14
days, and 237 patients received 300 mg daily dose for a median of 9 days.
Table 6 presents treatment-emergent adverse reactions observed in patients treated with
posaconazole injection 300 mg daily dose in the posaconazole injection study. Each patient received a
loading dose, 300 mg twice on Day 1. Following posaconazole intravenous therapy, patients received
posaconazole oral suspension to complete 28 days of total posaconazole therapy.
Table 6: Posaconazole Injection Study 1: Number (%) of Subjects Treated with Posaconazole
Injection 300 mg Daily Dose Reporting Treatment-Emergent Adverse Reactions: Frequency of
at Least 10%
Body System Posaconazole Posaconazole
Injection Injection
Preferred Term Treatment Phase Treatment Phase
n=237 (%)* or Subsequent
Oral Suspension
Treatment Phase
n=237(%)†
Subjects Reporting any Adverse Reaction 220 (93) 235 (99)
Blood and Lymphatic System Disorder
Anemia 16 (7) 23 (10)
Thrombocytopenia 17 (7) 25 (11)
Gastrointestinal Disorders
Abdominal Pain Upper 15 (6) 25 (11)
Abdominal Pain 30 (13) 41 (17)
Constipation 18 (8) 31 (13)
Diarrhea 75 (32) 93 (39)
Nausea 46 (19) 70 (30)
Vomiting 29 (12) 45 (19)
General Disorders and Administration Site Conditions
Fatigue 19 (8) 24 (10)
Chills 28 (12) 38 (16)
Edema Peripheral 28 (12) 35 (15)
Pyrexia 49 (21) 73 (31)
Metabolism and Nutrition Disorders
Decreased appetite 23 (10) 29 (12)
Hypokalemia 51 (22) 67 (28)
Hypomagnesemia 25 (11) 30 (13)

Nervous System Disorders
Headache 33 (14) 49 (21)
Respiratory, Thoracic and Mediastinal Disorders
Cough 21 (9) 31 (13)
Dyspnea 16 (7) 24 (10)
Epistaxis 34 (14) 40 (17)
Skin and Subcutaneous Tissue Disorders
Petechiae 20 (8) 24 (10)
Rash 35 (15) 56 (24)
Vascular Disorders
Hypertension 20 (8) 26 (11)

*Adverse reactions reported in patients with an onset during the posaconazole intravenous dosing
phase of the study.
†Adverse reactions reported with an onset at any time during the study in patients who were
treated for up to 28 days of posaconazole therapy.
The most frequently reported adverse reactions with an onset during the posaconazole intravenous
phase of dosing with 300 mg once daily were diarrhea (32%), hypokalemia (22%), pyrexia (21%), and
nausea (19%). These adverse reactions were consistent with those seen in studies with Noxafil oral
suspension.
Clinical Trial Experience with Posaconazole Delayed-Release Tablets
The safety of posaconazole delayed-release tablets has been assessed in 230 patients in clinical
trials. Patients were enrolled in a non-comparative pharmacokinetic and safety trial of posaconazole
delayed-release tablets when given as antifungal prophylaxis (Delayed-Release Tablet Study 1). Patients
were immunocompromised with underlying conditions including hematological malignancy, neutropenia
post-chemotherapy, GVHD, and post HSCT. This patient population was 62% male, had a mean age of
51 years (range 19-78 years, 17% of patients were ≥65 years of age), and were 93% white and 16%
Hispanic. Posaconazole therapy was given for a median duration of 28 days. Twenty patients received
200 mg daily dose and 210 patients received 300 mg daily dose (following twice daily dosing on Day 1 in
each cohort). Table 7 presents treatment-emergent adverse reactions observed in patients treated with
300 mg daily dose at an incidence of ≥10% in posaconazole delayed-release tablet study.
Table 7: Posaconazole Delayed-Release Tablet Study 1: Number (%) of Subjects Treated with
300 mg Daily Dose Reporting Treatment-Emergent Adverse Reactions: Frequency of at Least 10%
Body System Posaconazole
delayed-release
Preferred Term tablet (300 mg)
(n=210)
Subjects Reporting any Adverse Reaction 201 (99)
Blood and Lymphatic System Disorder
Anemia 22 (10)
Thrombocytopenia 29 (14)
Gastrointestinal Disorders
Abdominal Pain 23 (11)
Constipation 20 (10)
10

Diarrhea 61 (29)
Nausea 56 (27)
Vomiting 28 (13)
General Disorders and Administration Site Conditions
Asthenia 20 (10)
Chills 22 (10)
Mucosal Inflammation 29 (14)
Edema Peripheral 33 (16)
Pyrexia 59 (28)
Metabolism and Nutrition Disorders
Hypokalemia 46 (22)
Hypomagnesemia 20 (10)
Nervous System Disorders
Headache 30 (14)
Respiratory, Thoracic and Mediastinal Disorders
Cough 35 (17)
Epistaxis 30 (14)
Rash 34 (16)
Vascular Disorders
Hypertension 23 (11)
The most frequently reported adverse reactions (>25%) with posaconazole delayed-release tablets
300 mg once daily were diarrhea, pyrexia, and nausea.
The most common adverse reaction leading to discontinuation of posaconazole delayed-release
tablets 300 mg once daily was nausea (2%).
Clinical Trial Safety Experience with Posaconazole Oral Suspension
The safety of posaconazole oral suspension has been assessed in 1844 patients. This includes 605
patients in the active-controlled prophylaxis studies, 557 patients in the active-controlled OPC studies,
239 patients in refractory OPC studies, and 443 patients from other indications. This represents a
heterogeneous population, including immunocompromised patients, e.g., patients with hematological
malignancy, neutropenia post-chemotherapy, GVHD post HSCT, and HIV infection, as well as non
neutropenic patients. This patient population was 71% male, had a mean age of 42 years (range 8-84
years, 6% of patients were ≥65 years of age and 1% was <18 years of age), and were 64% white, 16%
Hispanic, and 36% non-white (including 14% black). Posaconazole therapy was given to 171 patients for
≥6 months, with 58 patients receiving posaconazole therapy for ≥12 months. Table 8 presents treatment-
emergent adverse reactions observed at an incidence of >10% in posaconazole prophylaxis studies.
Table 9 presents treatment-emergent adverse reactions observed at an incidence of at least 10% in the
OPC/rOPC studies.
Prophylaxis of Aspergillus and Candida: In the 2 randomized, comparative prophylaxis studies
(Oral Suspension Studies 1 and 2), the safety of posaconazole oral suspension 200 mg three times a day
was compared to fluconazole 400 mg once daily or itraconazole 200 mg twice a day in severely
immunocompromised patients.
11

The most frequently reported adverse reactions (>30%) in the prophylaxis clinical trials were fever,
diarrhea, and nausea.
The most common adverse reactions leading to discontinuation of posaconazole in the prophylaxis
studies were associated with GI disorders, specifically, nausea (2%), vomiting (2%), and hepatic enzymes
increased (2%).
Table 8: Posaconazole Oral Suspension Study 1 and Study 2. Number (%) of Randomized Subjects
Reporting Treatment-Emergent Adverse Reactions: Frequency of at Least 10% in the Posaconazole
Oral Suspension or Fluconazole Treatment Groups (Pooled Prophylaxis Safety Analysis)
Body System Posaconazole Fluconazole Itraconazole

(n=605) (n=539) (n=58)
Preferred Term
Subjects Reporting any Adverse Reaction 595 (98) 531 (99) 58 (100)
Body as a Whole - General Disorders
Fever 274 (45) 254 (47) 32 (55)
Headache 171 (28) 141 (26) 23 (40)
Rigors 122 (20) 87 (16) 17 (29)
Fatigue 101 (17) 98 (18) 5 (9)
Edema Legs 93 (15) 67 (12) 11 (19)
Anorexia 92 (15) 94 (17) 16 (28)
Dizziness 64 (11) 56 (10) 5 (9)
Edema 54 (9) 68 (13) 8 (14)
Weakness 51 (8) 52 (10) 2 (3)
Cardiovascular Disorders, General
Hypertension 106 (18) 88 (16) 3 (5)
Hypotension 83 (14) 79 (15) 10 (17)
Disorders of Blood and Lymphatic System
Anemia 149 (25) 124 (23) 16 (28)
Neutropenia 141 (23) 122 (23) 23 (40)
Disorders of the Reproductive System and Breast
Vaginal Hemorrhage* 24 (10) 20 (9) 3 (12)
Gastrointestinal System Disorders
Diarrhea 256 (42) 212 (39) 35 (60)
Nausea 232 (38) 198 (37) 30 (52)
Vomiting 174 (29) 173 (32) 24 (41)
Abdominal Pain 161 (27) 147 (27) 21 (36)
Constipation 126 (21) 94 (17) 10 (17)
Dyspepsia 61 (10) 50 (9) 6 (10)
Heart Rate and Rhythm Disorders
12

Tachycardia 72 (12) 75 (14) 3 (5)
Infection and Infestations
Pharyngitis 71 (12) 60 (11) 12 (21)
Liver and Biliary System Disorders
Bilirubinemia 59 (10) 51 (9) 11 (19)
Metabolic and Nutritional Disorders
Hypokalemia 181 (30) 142 (26) 30 (52)
Hypomagnesemia 110 (18) 84 (16) 11 (19)
Hyperglycemia 68 (11) 76 (14) 2 (3)
Hypocalcemia 56 (9) 55 (10) 5 (9)
Musculoskeletal System Disorders
Musculoskeletal Pain 95 (16) 82 (15) 9 (16)
Arthralgia 69 (11) 67 (12) 5 (9)
Back Pain 63 (10) 66 (12) 4 (7)
Platelet, Bleeding and Clotting Disorders
Thrombocytopenia 175 (29) 146 (27) 20 (34)
Petechiae 64 (11) 54 (10) 9 (16)
Psychiatric Disorders
Insomnia 103 (17) 92 (17) 11 (19)
Respiratory System Disorders
Coughing 146 (24) 130 (24) 14 (24)
Dyspnea 121 (20) 116 (22) 15 (26)
Epistaxis 82 (14) 73 (14) 12 (21)
Rash 113 (19) 96 (18) 25 (43)
Pruritus 69 (11) 62 (12) 11 (19)

* Percentages of sex-specific adverse reactions are based on the number of males/females.
HIV Infected Subjects with OPC: In 2 randomized comparative studies in OPC, the safety of
posaconazole oral suspension at a dose of less than or equal to 400 mg QD in 557 HIV-infected patients
was compared to the safety of fluconazole in 262 HIV-infected patients at a dose of 100 mg QD.
An additional 239 HIV-infected patients with refractory OPC received posaconazole oral suspension in
2 non-comparative trials for refractory OPC (rOPC). Of these subjects, 149 received the 800-mg/day dose
and the remainder received the less than or equal to 400-mg QD dose.
In the OPC/rOPC studies, the most common adverse reactions were fever, diarrhea, nausea,
headache, vomiting, and coughing.
The most common adverse reactions that led to treatment discontinuation of posaconazole in the
Controlled OPC Pool included respiratory impairment (1%) and pneumonia (1%). In the refractory OPC
13

pool, the most common adverse reactions that led to treatment discontinuation of posaconazole were
AIDS (7%) and respiratory impairment (3%).
Table 9: Treatment-Emergent Adverse Reactions with Frequency of at Least 10% in OPC Studies
with Posaconazole Oral Suspension (Treated Population)
Number (%) of Subjects
Controlled OPC Pool Refractory OPC Pool
Body System Posaconazole Fluconazole Posaconazole
Preferred Term n=557 n=262 n=239
Subjects Reporting any Adverse Reaction* 356 (64) 175 (67) 221 (92)
Body as a Whole – General Disorders
Fever 34 (6) 22 (8) 82 (34)
Headache 44 (8) 23 (9) 47 (20)
Anorexia 10 (2) 4 (2) 46 (19)
Fatigue 18 (3) 12 (5) 31 (13)
Asthenia 9 (2) 5 (2) 31 (13)
Rigors 2 (<1) 4 (2) 29 (12)
Pain 4 (1) 2 (1) 27 (11)
Disorders of Blood and Lymphatic System
Neutropenia 21 (4) 8 (3) 39 (16)
Anemia 11 (2) 5 (2) 34 (14)
Gastrointestinal System Disorders
Diarrhea 58 (10) 34 (13) 70 (29)
Nausea 48 (9) 30 (11) 70 (29)
Vomiting 37 (7) 18 (7) 67 (28)
Abdominal Pain 27 (5) 17 (6) 43 (18)
Infection and Infestations
Candidiasis, Oral 3 (1) 1 (<1) 28 (12)
Herpes Simplex 16 (3) 8 (3) 26 (11)
Pneumonia 17 (3) 6 (2) 25 (10)
Metabolic and Nutritional Disorders
Weight Decrease 4 (1) 2 (1) 33 (14)
Dehydration 4 (1) 7 (3) 27 (11)
Psychiatric Disorders
Insomnia 8 (1) 3 (1) 39 (16)
Respiratory System Disorders
Coughing 18 (3) 11 (4) 60 (25)
Dyspnea 8 (1) 8 (3) 28 (12)
Rash 15 (3) 10 (4) 36 (15)
Sweating Increased 13 (2) 5 (2) 23 (10)
OPC=oropharyngeal candidiasis
* Number of subjects reporting treatment-emergent adverse reactions at least once during the study,
without regard to relationship to treatment. Subjects may have reported more than 1 event.
Adverse reactions were reported more frequently in the pool of patients with refractory OPC. Among
these highly immunocompromised patients with advanced HIV disease, serious adverse reactions (SARs)
were reported in 55% (132/239). The most commonly reported SARs were fever (13%) and neutropenia
(10%).
Less Common Adverse Reactions: Clinically significant adverse reactions reported during clinical
trials in prophylaxis, OPC/rOPC or other trials with posaconazole which occurred in less than 5% of
patients are listed below:
• Blood and lymphatic system disorders: hemolytic uremic syndrome, thrombotic
thrombocytopenic purpura, neutropenia aggravated
• Endocrine disorders: adrenal insufficiency

• Nervous system disorders: paresthesia
• Immune system disorders: allergic reaction [see Contraindications (4.1)]
• Cardiac disorders: torsades de pointes [see Warnings and Precautions (5.2)]
• Vascular disorders: pulmonary embolism
14

• Liver and Biliary System Disorders: bilirubinemia, hepatic enzymes increased, hepatic function
abnormal, hepatitis, hepatomegaly, jaundice, AST Increased, ALT Increased
• Metabolic and Nutritional Disorders: hypokalemia
• Platelet, Bleeding, and Clotting Disorders: thrombocytopenia
• Renal & Urinary System Disorders: renal failure acute
Clinical Laboratory Values: In healthy volunteers and patients, elevation of liver function test values
did not appear to be associated with higher plasma concentrations of posaconazole.
For the prophylaxis studies, the number of patients with changes in liver function tests from Common
Toxicity Criteria (CTC) Grade 0, 1, or 2 at baseline to Grade 3 or 4 during the study is presented in Table
10.
Table 10: Posaconazole Oral Suspension Study 1 and Study 2. Changes in Liver Function Test
Results from CTC Grade 0, 1, or 2 at Baseline to Grade 3 or 4
Number (%) of Patients With Change*
Oral Suspension Study 1
Posaconazole Fluconazole
Laboratory Parameter n=301 n=299
AST 11/266 (4) 13/266 (5)
ALT 47/271 (17) 39/272 (14)
Bilirubin 24/271 (9) 20/275 (7)
Alkaline Phosphatase 9/271 (3) 8/271 (3)
Posaconazole Fluconazole/Itraconazole
Laboratory Parameter (n=304) (n=298)
AST 9/286 (3) 5/280 (2)
ALT 18/289 (6) 13/284 (5)
Bilirubin 20/290 (7) 25/285 (9)
Alkaline Phosphatase 4/281 (1) 1/276 (<1)
*Change from Grade 0 to 2 at baseline to Grade 3 or 4 during the study. These
data are presented in the form X/Y, where X represents the number of
patients who met the criterion as indicated, and Y represents the number of
patients who had a baseline observation and at least one post-baseline
observation.
CTC = Common Toxicity Criteria; AST= Aspartate Aminotransferase;
ALT= Alanine Aminotransferase.
The number of patients treated for OPC with clinically significant liver function test (LFT) abnormalities
at any time during the studies is provided in Table 11 (LFT abnormalities were present in some of these
patients prior to initiation of the study drug).
Table 11: Posaconazole Oral Suspension Studies: Clinically Significant Laboratory Test
Abnormalities without Regard to Baseline Value
Controlled Refractory
Posaconazole Fluconazole Posaconazole
Laboratory Test n=557(%) n=262(%) n=239(%)
ALT > 3.0 x ULN 16/537 (3) 13/254 (5) 25/226 (11)
AST > 3.0 x ULN 33/537 (6) 26/254 (10) 39/223 (17)
Total Bilirubin > 1.5 x ULN 15/536 (3) 5/254 (2) 9/197 (5)
Alkaline Phosphatase > 3.0 x ULN 17/535 (3) 15/253 (6) 24/190 (13)
15

ALT= Alanine Aminotransferase; AST= Aspartate Aminotransferase.
6.3 Postmarketing Experience

No clinically significant postmarketing adverse reactions were identified that have not previously been
reported during clinical trials experience.
7 DRUG INTERACTIONS
Posaconazole is primarily metabolized via UDP glucuronosyltransferase and is a substrate of p
glycoprotein (P-gp) efflux. Therefore, inhibitors or inducers of these clearance pathways may affect
posaconazole plasma concentrations. Coadministration of drugs that can decrease the plasma
concentrations of posaconazole should generally be avoided unless the benefit outweighs the risk. If such
drugs are necessary, patients should be monitored closely for breakthrough fungal infections.
Posaconazole is also a strong inhibitor of CYP3A4. Therefore, plasma concentrations of drugs
predominantly metabolized by CYP3A4 may be increased by posaconazole [see Clinical Pharmacology
(12.3)].
The following information was derived from data with posaconazole oral suspension or early tablet
formulation. All drug interactions with posaconazole oral suspension, except for those that affect the
absorption of posaconazole (via gastric pH and motility) are considered relevant to posaconazole
injection as well [see Drug Interactions (7.9) and (7.13)].
7.1 Immunosuppressants Metabolized by CYP3A4
Sirolimus: Concomitant administration of posaconazole with sirolimus increases the sirolimus blood
concentrations by approximately 9-fold and can result in sirolimus toxicity. Therefore, posaconazole is
contraindicated with sirolimus [see Contraindications (4.2) and Clinical Pharmacology (12.3)].
Tacrolimus: Posaconazole has been shown to significantly increase the Cmax and AUC of tacrolimus.
At initiation of posaconazole treatment, reduce the tacrolimus dose to approximately one-third of the
original dose. Frequent monitoring of tacrolimus whole blood trough concentrations should be performed
during and at discontinuation of posaconazole treatment and the tacrolimus dose adjusted accordingly
[see Warnings and Precautions (5.1) and Clinical Pharmacology (12.3)].
Cyclosporine: Posaconazole has been shown to increase cyclosporine whole blood concentrations in
heart transplant patients upon initiation of posaconazole treatment. It is recommended to reduce
cyclosporine dose to approximately three-fourths of the original dose upon initiation of posaconazole
treatment. Frequent monitoring of cyclosporine whole blood trough concentrations should be performed
during and at discontinuation of posaconazole treatment and the cyclosporine dose adjusted accordingly
[see Warnings and Precautions (5.1) and Clinical Pharmacology (12.3)].
7.2 CYP3A4 Substrates
Concomitant administration of posaconazole with CYP3A4 substrates such as pimozide and quinidine
may result in increased plasma concentrations of these drugs, leading to QTc prolongation and cases of
torsades de pointes. Therefore, posaconazole is contraindicated with these drugs [see Contraindications
(4.3) and Warnings and Precautions (5.2)].
7.3 HMG-CoA Reductase Inhibitors (Statins) Primarily Metabolized Through CYP3A4
Concomitant administration of posaconazole with simvastatin increases the simvastatin plasma
concentrations by approximately 10-fold. Therefore, posaconazole is contraindicated with HMG-CoA
reductase inhibitors primarily metabolized through CYP3A4 [see Contraindications (4.4) and Clinical
7.4 Ergot Alkaloids
Most of the ergot alkaloids are substrates of CYP3A4. Posaconazole may increase the plasma
concentrations of ergot alkaloids (ergotamine and dihydroergotamine) which may lead to ergotism.
Therefore, posaconazole is contraindicated with ergot alkaloids [see Contraindications (4.5)].
7.5 Benzodiazepines Metabolized by CYP3A4
Concomitant administration of posaconazole with midazolam increases the midazolam plasma
concentrations by approximately 5-fold. Increased plasma midazolam concentrations could potentiate and
prolong hypnotic and sedative effects. Concomitant use of posaconazole and other benzodiazepines
metabolized by CYP3A4 (e.g., alprazolam, triazolam) could result in increased plasma concentrations of
16

these benzodiazepines. Patients must be monitored closely for adverse effects associated with high
plasma concentrations of benzodiazepines metabolized by CYP3A4 and benzodiazepine receptor
antagonists must be available to reverse these effects [see Warnings and Precautions (5.5) and Clinical
7.6 Anti-HIV Drugs
Efavirenz: Efavirenz induces UDP-glucuronidase and significantly decreases posaconazole plasma
concentrations [see Clinical Pharmacology (12.3)]. It is recommended to avoid concomitant use of
efavirenz with posaconazole unless the benefit outweighs the risks.
Ritonavir and Atazanavir: Ritonavir and atazanavir are metabolized by CYP3A4 and posaconazole
increases plasma concentrations of these drugs [see Clinical Pharmacology (12.3)]. Frequent monitoring
of adverse effects and toxicity of ritonavir and atazanavir should be performed during coadministration
with posaconazole.
Fosamprenavir: Combining fosamprenavir with posaconazole may lead to decreased posaconazole
plasma concentrations. If concomitant administration is required, close monitoring for breakthrough fungal
infections is recommended [see Clinical Pharmacology (12.3)].
7.7 Rifabutin
Rifabutin induces UDP-glucuronidase and decreases posaconazole plasma concentrations. Rifabutin
is also metabolized by CYP3A4. Therefore, coadministration of rifabutin with posaconazole increases
rifabutin plasma concentrations [see Clinical Pharmacology (12.3)]. Concomitant use of posaconazole
and rifabutin should be avoided unless the benefit to the patient outweighs the risk. However, if
concomitant administration is required, close monitoring for breakthrough fungal infections as well as
frequent monitoring of full blood counts and adverse reactions due to increased rifabutin plasma
concentrations (e.g., uveitis, leukopenia) are recommended.
7.8 Phenytoin
Phenytoin induces UDP-glucuronidase and decreases posaconazole plasma concentrations.
Phenytoin is also metabolized by CYP3A4. Therefore, coadministration of phenytoin with posaconazole
increases phenytoin plasma concentrations [see Clinical Pharmacology (12.3)]. Concomitant use of
posaconazole and phenytoin should be avoided unless the benefit to the patient outweighs the risk.
However, if concomitant administration is required, close monitoring for breakthrough fungal infections is
recommended and frequent monitoring of phenytoin concentrations should be performed while
coadministered with posaconazole and dose reduction of phenytoin should be considered.
7.9 Gastric Acid Suppressors/Neutralizers
Posaconazole Delayed-Release Tablet:
No clinically relevant effects on the pharmacokinetics of posaconazole were observed when
posaconazole delayed-release tablets are concomitantly used with antacids, H2-receptor antagonists and
proton pump inhibitors [see Clinical Pharmacology (12.3)]. No dosage adjustment of posaconazole
delayed-release tablets is required when posaconazole delayed-release tablets are concomitantly used
with antacids, H2-receptor antagonists and proton pump inhibitors.
Posaconazole Oral Suspension:
Cimetidine (an H2-receptor antagonist) and esomeprazole (a proton pump inhibitor) when given with
posaconazole oral suspension results in decreased posaconazole plasma concentrations [see Clinical
Pharmacology (12.3)]. It is recommended to avoid concomitant use of cimetidine and esomeprazole with
posaconazole oral suspension unless the benefit outweighs the risks. However, if concomitant
administration is required, close monitoring for breakthrough fungal infections is recommended.
No clinically relevant effects were observed when posaconazole oral suspension is concomitantly
used with antacids and H2-receptor antagonists other than cimetidine. No dosage adjustment of
posaconazole oral suspension is required when posaconazole oral suspension is concomitantly used with
antacids and H2-receptor antagonists other than cimetidine.
7.10 Vinca Alkaloids
Most of the vinca alkaloids are substrates of CYP3A4. Posaconazole may increase the plasma
concentrations of vinca alkaloids (e.g., vincristine and vinblastine) which may lead to neurotoxicity.
Therefore, it is recommended that dose adjustment of the vinca alkaloid be considered.
7.11 Calcium Channel Blockers Metabolized by CYP3A4
17

Posaconazole may increase the plasma concentrations of calcium channel blockers metabolized by
CYP3A4 (e.g., verapamil, diltiazem, nifedipine, nicardipine, felodipine). Frequent monitoring for adverse
reactions and toxicity related to calcium channel blockers is recommended during coadministration. Dose
reduction of calcium channel blockers may be needed.
7.12 Digoxin
Increased plasma concentrations of digoxin have been reported in patients receiving digoxin and
posaconazole. Therefore, monitoring of digoxin plasma concentrations is recommended during
coadministration.
7.13 Gastrointestinal Motility Agents
Posaconazole Delayed-Release Tablet:
Concomitant administration of metoclopramide with posaconazole delayed-release tablets did not
affect the pharmacokinetics of posaconazole [see Clinical Pharmacology (12.3)]. No dosage adjustment
of posaconazole delayed-release tablets is required when given concomitantly with metoclopramide.
Posaconazole Oral Suspension:
Metoclopramide, when given with posaconazole oral suspension, decreases posaconazole plasma
concentrations [see Clinical Pharmacology (12.3)]. If metoclopramide is concomitantly administered with
posaconazole oral suspension, it is recommended to closely monitor for breakthrough fungal infections.
Loperamide does not affect posaconazole plasma concentrations after posaconazole oral suspension
administration [see Clinical Pharmacology (12.3)]. No dosage adjustment of posaconazole is required
when loperamide and posaconazole are used concomitantly.
7.14 Glipizide
Although no dosage adjustment of glipizide is required, it is recommended to monitor glucose
concentrations when posaconazole and glipizide are concomitantly used.
8 USE IN SPECIFIC POPULATIONS

8.1 Pregnancy
There are no adequate and well-controlled studies in pregnant women. Noxafil should be used in
pregnancy only if the potential benefit outweighs the potential risk to the fetus.
Posaconazole has been shown to cause skeletal malformations (cranial malformations and missing
ribs) in rats when given in doses ≥27 mg/kg (≥1.4 times the 400-mg BID oral suspension regimen based
on steady-state plasma concentrations of drug in healthy volunteers). The no-effect dose for
malformations in rats was 9 mg/kg, which is 0.7 times the exposure achieved with the 400-mg BID oral
suspension regimen. No malformations were seen in rabbits at doses up to 80 mg/kg. In the rabbit, the
no-effect dose was 20 mg/kg, while high doses of 40 mg/kg and 80 mg/kg, 2.9 or 5.2 times the exposure
achieved with the 400-mg BID oral suspension regimen, caused an increase in resorptions. In rabbits
dosed at 80 mg/kg, a reduction in body weight gain of females and a reduction in litter size were seen.
8.3 Nursing Mothers
Posaconazole is excreted in milk of lactating rats. It is not known whether Noxafil is excreted in human
milk. Because of the potential for serious adverse reactions from Noxafil in nursing infants, a decision
should be made whether to discontinue nursing or to discontinue the drug, taking into account the
importance of the drug to the mother.
8.4 Pediatric Use
The safety and effectiveness of Noxafil injection in pediatric patients below the age of 18 years of age
has not been established. Noxafil injection should not be used in pediatric patients because of nonclinical
safety concerns [see Nonclinical Toxicology (13.2)].
The safety and effectiveness of posaconazole oral suspension and posaconazole delayed-release
tablets have been established in the age groups 13 to 17 years of age. Use of posaconazole in these age
groups is supported by evidence from adequate and well-controlled studies of posaconazole in adults.
The safety and effectiveness of posaconazole in pediatric patients below the age of 13 years have not
been established.
A total of 12 patients 13 to 17 years of age received 600 mg/day (200 mg three times a day) of
posaconazole oral suspension for prophylaxis of invasive fungal infections. The safety profile in these
patients <18 years of age appears similar to the safety profile observed in adults. Based on
18

pharmacokinetic data in 10 of these pediatric patients, the mean steady-state average posaconazole
concentration (Cavg) was similar between these patients and adults (≥18 years of age).
A total of 16 patients 8 to 17 years of age were treated with 800 mg/day (400 mg twice a day or
200 mg four times a day) of posaconazole oral suspension in a study for another indication. Based on
pharmacokinetic data in 12 of these pediatric patients, the mean steady-state average posaconazole
concentration (Cavg) was similar between these patients and adults (≥18 years of age).
In the prophylaxis studies, the mean steady-state posaconazole average concentration (Cavg) was
similar among ten adolescents (13 to 17 years of age) and adults (≥18 years of age). This is consistent
with pharmacokinetic data from another study in which mean steady-state posaconazole Cavg from 12
adolescent patients (8 to 17 years of age) was similar to that in the adults (≥18 years of age).
8.5 Geriatric Use
Of the 279 patients treated with posaconazole injection, 52 (19%) were greater than 65 years of age.
The pharmacokinetics of posaconazole injection are comparable in young and elderly subjects. No overall
differences in safety were observed between the geriatric patients and younger patients; therefore, no
dosage adjustment is recommended for Noxafil injection in geriatric patients.
Of the 230 patients treated with posaconazole delayed-release tablets, 38 (17%) were greater than 65
years of age. The pharmacokinetics of posaconazole delayed-release tablets are comparable in young
and elderly subjects. No overall differences in safety were observed between the geriatric patients and
younger patients; therefore, no dosage adjustment is recommended for geriatric patients.
Of the 605 patients randomized to posaconazole oral suspension in the prophylaxis clinical trials, 63
(10%) were ≥65 years of age. In addition, 48 patients treated with greater than or equal to 800-mg/day
posaconazole in another indication were ≥65 years of age. No overall differences in safety were observed
between the geriatric patients and younger patients.
The pharmacokinetics of posaconazole oral suspension are comparable in young and elderly subjects
(≥65 years of age); therefore no adjustment in the dosage of Noxafil oral suspension is necessary in
geriatric patients.
No overall differences in the pharmacokinetics and safety were observed between elderly and young
subjects during clinical trials, but greater sensitivity of some older individuals cannot be ruled out.
8.6 Renal Impairment
Following single-dose administration of 400 mg of the oral suspension, there was no significant effect
2 2
of mild (eGFR: 50-80 mL/min/1.73 m , n=6) or moderate (eGFR: 20-49 mL/min/1.73 m , n=6) renal
impairment on posaconazole pharmacokinetics; therefore, no dose adjustment is required in patients with
mild to moderate renal impairment. In subjects with severe renal impairment (eGFR: <20 mL/min/1.73
2
m ), the mean plasma exposure (AUC) was similar to that in patients with normal renal function (eGFR:
2
>80 mL/min/1.73 m ); however, the range of the AUC estimates was highly variable (CV=96%) in these
subjects with severe renal impairment as compared to that in the other renal impairment groups
(CV<40%). Due to the variability in exposure, patients with severe renal impairment should be monitored
closely for breakthrough fungal infections [see Dosage and Administration (2)]. Similar recommendations
apply to posaconazole delayed-release tablets; however, a specific study has not been conducted with
the delayed-release tablets.
Noxafil injection should be avoided in patients with moderate or severe renal impairment (eGFR <50
mL/min), unless an assessment of the benefit/risk to the patient justifies the use of Noxafil injection. In
patients with moderate or severe renal impairment (eGFR <50 mL/min), receiving the Noxafil injection,
accumulation of the intravenous vehicle, SBECD, is expected to occur. Serum creatinine levels should be
closely monitored in these patients, and, if increases occur, consideration should be given to changing to
oral Noxafil therapy [see Dosage and Administration (2.6) and Warnings and Precautions (5.4)].
8.7 Hepatic Impairment
After a single oral dose of posaconazole oral suspension 400 mg, the mean AUC was 43%, 27%, and
21% higher in subjects with mild (Child-Pugh Class A, N=6), moderate (Child-Pugh Class B, N=6), or
severe (Child-Pugh Class C, N=6) hepatic impairment, respectively, compared to subjects with normal
hepatic function (N=18). Compared to subjects with normal hepatic function, the mean Cmax was 1%
higher, 40% higher, and 34% lower in subjects with mild, moderate, or severe hepatic impairment,
respectively. The mean apparent oral clearance (CL/F) was reduced by 18%, 36%, and 28% in subjects
with mild, moderate, or severe hepatic impairment, respectively, compared to subjects with normal
19

hepatic function. The elimination half-life (t½) was 27 hours, 39 hours, 27 hours, and 43 hours in subjects
with normal hepatic function and mild, moderate, or severe hepatic impairment, respectively.
It is recommended that no dose adjustment of Noxafil is needed in patients with mild to severe hepatic
impairment (Child-Pugh Class A, B, or C) [see Dosage and Administration (2) and Warnings and
Precautions (5.3)]. Similar recommendations apply to posaconazole delayed-release tablets; however, a
specific study has not been conducted with the delayed-release tablets.
Similar recommendations apply to posaconazole injection; however, a specific study has not been
conducted with the posaconazole injection.
8.8 Gender
The pharmacokinetics of posaconazole are comparable in men and women. No adjustment in the
dosage of Noxafil is necessary based on gender.
8.9 Race
The pharmacokinetic profile of posaconazole is not significantly affected by race. No adjustment in the
dosage of Noxafil is necessary based on race.
8.10 Weight
Pharmacokinetic modeling suggests that patients weighing greater than 120 kg may have lower
posaconazole plasma drug exposure. It is, therefore, suggested to closely monitor for breakthrough
fungal infections.
10 OVERDOSAGE
There is no experience with overdosage of posaconazole injection and delayed-release tablets.
During the clinical trials, some patients received posaconazole oral suspension up to 1600 mg/day
with no adverse reactions noted that were different from the lower doses. In addition, accidental overdose
was noted in one patient who took 1200 mg BID posaconazole oral suspension for 3 days. No related
adverse reactions were noted by the investigator.
Posaconazole is not removed by hemodialysis.
11 DESCRIPTION
Noxafil is an azole antifungal agent available as concentrated solution to be diluted before intravenous
administration, delayed-release tablet, or suspension for oral administration.
Posaconazole is designated chemically as 4-[4-[4-[4-[[ (3R,5R)-5- (2,4-difluorophenyl)tetrahydro-5
(1H-1,2,4-triazol-1-ylmethyl)-3-furanyl]methoxy]phenyl]-1-piperazinyl]phenyl]-2-[(1S,2S)-1-ethyl-2
hydroxypropyl]-2,4-dihydro-3H-1,2,4-triazol-3-one with an empirical formula of C37H42F2N8O4 and a
molecular weight of 700.8. The chemical structure is:
O
CH3
F F O N N N N
N OH
H3C
O
N N
Posaconazole is a white powder with a low aqueous solubility.

Noxafil injection is available as a clear colorless to yellow, sterile liquid essentially free of foreign
matter. Each vial contains 300 mg of posaconazole and the following inactive ingredients: 6.68 g Betadex
Sulfobutyl Ether Sodium (SBECD), 0.003 g edetate disodium, hydrochloric acid and sodium hydroxide to
adjust the pH to 2.6, and water for injection.
Noxafil delayed-release tablet is a yellow, coated, oblong tablet containing 100 mg of posaconazole.
Each delayed-release tablet contains the inactive ingredients: hypromellose acetate succinate,
microcrystalline cellulose, hydroxypropylcellulose, silicon dioxide, croscarmellose sodium, magnesium
20

stearate, and Opadry® II Yellow (consists of the following ingredients: polyvinyl alcohol partially
hydrolyzed, Macrogol/PEG 3350, titanium dioxide, talc, and iron oxide yellow).
Noxafil oral suspension is a white, cherry-flavored immediate-release suspension containing 40 mg of
posaconazole per mL and the following inactive ingredients: polysorbate 80, simethicone, sodium
benzoate, sodium citrate dihydrate, citric acid monohydrate, glycerin, xanthan gum, liquid glucose,
titanium dioxide, artificial cherry flavor, and purified water.
12 CLINICAL PHARMACOLOGY
12.1 Mechanism of Action
Posaconazole is an azole antifungal agent [see Clinical Pharmacology (12.4)].
12.2 Pharmacodynamics
Exposure Response Relationship: In clinical studies of neutropenic patients who were receiving
cytotoxic chemotherapy for acute myelogenous leukemia (AML) or myelodysplastic syndromes (MDS) or
hematopoietic stem cell transplant (HSCT) recipients with Graft versus Host Disease (GVHD), a wide
range of plasma exposures to posaconazole was noted following administration of Noxafil oral
suspension. A pharmacokinetic-pharmacodynamic analysis of patient data revealed an apparent
association between average posaconazole concentrations (Cavg) and prophylactic efficacy (Table 12).
A lower Cavg may be associated with an increased risk of treatment failure, defined as treatment
discontinuation, use of empiric systemic antifungal therapy (SAF), or occurrence of breakthrough invasive
fungal infections.
Table 12: Noxafil Oral Suspension Exposure Analysis (Cavg) in Prophylaxis Trials
Prophylaxis in AML/MDS* Prophylaxis in GVHD†
Cavg Range (ng/mL) Treatment Failure‡ (%) Cavg Range (ng/mL) Treatment Failure‡
(%)
Quartile 1 90-322 54.7 22-557 44.4
Quartile 2 322-490 37.0 557-915 20.6
Quartile 3 490-734 46.8 915-1563 17.5
Quartile 4 734-2200 27.8 1563-3650 17.5

Cavg = the average posaconazole concentration when measured at steady state
* Neutropenic patients who were receiving cytotoxic chemotherapy for AML or MDS
†
HSCT recipients with GVHD
‡
Defined as treatment discontinuation, use of empiric systemic antifungal therapy (SAF), or occurrence of
breakthrough invasive fungal infections
12.3 Pharmacokinetics
General Pharmacokinetic Characteristics
Posaconazole Injection
Posaconazole injection exhibits dose proportional pharmacokinetics after single doses between 200
and 300 mg in healthy volunteers and patients. The mean pharmacokinetic parameters after single doses
with posaconazole injection in healthy volunteers and patients are shown in Table 13.
Table 13: Summary of Mean Pharmacokinetic Parameters (%CV) in Healthy Volunteers (30 minute
infusion via peripheral venous line) and Patients (90 minute infusion via central venous line) after
Dosing with Posaconazole Injection on Day 1
Dose (mg) n AUC0-∞ AUC0-12 Cmax t1/2 CL
(ng·hr/mL) (ng·hr/mL) (ng/mL) (hr) (L/hr)
Healthy 200 9 35400 (50) 8840 (20) 2250 (29) 23.6 (23) 6.5 (32)
Volunteers 300 9 46400 (26) 13000 (13) 2840 (30) 24.6 (20) 6.9 (27)
Patients 200 30 N/D 5570 (32) 954 (44) N/D N/D
21

300 22 N/D 8240 (26) 1590 (62) N/D N/D
AUC0-∞ = Area under the plasma concentration-time curve from time zero to infinity; AUC0-12 = Area under the plasma concentration-
time curve from time zero to 12 hr after the first dose on Day 1; Cmax = maximum observed concentration; t½ = terminal phase half-
life; CL = total body clearance; N/D = Not Determined
Table 14 displays the pharmacokinetic parameters of posaconazole in patients following

administration of posaconazole injection 300 mg taken once a day for 10 or 14 days following BID dosing
on Day 1.
Table 14: Arithmetic Mean (%CV) of PK Parameters in Serial PK-Evaluable Patients Following
Dosing of Posaconazole Injection (300 mg)*
Cmax Tmax† AUC0-24 Cav Cmin
Day N
(ng/mL) (hr) (ng*hr/mL) (ng/mL) (ng/mL)
10/14 49 3280 (74) 1.5 (0.98-4.0) 36100 (35) 1500 (35) 1090 (44)
AUC0-24 = area under the concentration-time curve over the dosing interval (i.e. 24 hours); Cav= time-averaged concentrations
(i.e., AUC0-24h/24hr);
Cmin = POS trough level immediately before a subject received the dose of POS on the day specified in the protocol; Cmax =
observed maximum plasma concentration; CV = coefficient of variation, expressed as a percent (%); Day = study day on
treatment; Tmax = time of observed maximum plasma concentration.
* 300 mg dose administered over 90 minutes once a day following BID dosing on Day 1
†
Median (minimum-maximum)
Posaconazole Delayed-Release Tablets

Noxafil delayed-release tablets exhibit dose proportional pharmacokinetics after single and multiple
dosing up to 300 mg. The mean pharmacokinetic parameters of posaconazole at steady state following
administration of Noxafil delayed-release tablets 300 mg twice daily (BID) on Day 1, then 300 mg once
daily (QD) thereafter in healthy volunteers and in neutropenic patients who are receiving cytotoxic
chemotherapy for AML or MDS or HSCT recipients with GVHD are shown in Table 15.
Table 15: Arithmetic Mean (%CV) of Steady State PK Parameters in Healthy Volunteers and
Patients Following Administration of Posaconazole Delayed-Release Tablets (300 mg)*
N AUC0-24 hr Cav† Cmax Cmin Tmax‡ t1/2 CL/F
(ng·hr/mL) (ng/mL) (ng/mL) (ng/mL) (hr) (hr) (L/hr)
Healthy 12 51618 2151 2764 1785 4 31 7.5
Volunteers (25) (25) (21) (29) (3-6) (40) (26)
Patients 50 37900 1580 2090 1310 4 (1.3-8.3) - 9.39
(42) (42) (38) (50) (45)
CV = coefficient of variation expressed as a percentage (%CV); AUC0-T = Area under the plasma
concentration-time curve from time zero to 24 hr; Cmax = maximum observed concentration; Cmin =
minimum observed plasma concentration; Tmax = time of maximum observed concentration; t½ = terminal
phase half-life; CL /F = Apparent total body clearance
*300 mg BID on Day 1, then 300 mg QD thereafter
†
Cav = time-averaged concentrations (i.e., AUC0-24 hr/24hr)
‡
Median (minimum-maximum)
Posaconazole Oral Suspension

Dose-proportional increases in plasma exposure (AUC) to posaconazole oral suspension were
observed following single oral doses from 50 mg to 800 mg and following multiple-dose administration
from 50 mg BID to 400 mg BID in healthy volunteers. No further increases in exposure were observed
when the dose of the oral suspension increased from 400 mg BID to 600 mg BID in febrile neutropenic
patients or those with refractory invasive fungal infections.
22

The mean (%CV) [min-max] posaconazole oral suspension average steady-state plasma
concentrations (Cavg) and steady-state pharmacokinetic parameters in patients following administration
of 200 mg TID and 400 mg BID of the oral suspension are provided in Table 16.
Table 16: The Mean (%CV) [min-max] Posaconazole Steady-State Pharmacokinetic Parameters
in Patients Following Oral Administration of Posaconazole Oral Suspension 200 mg TID and
400 mg BID
AUC†
Dose* Cavg (ng/mL) CL/F (L/hr) V/F (L) t½ (hr)
(ng·hr/mL)
1103 (67)
200 mg TID‡ (n=252) ND§ ND§ ND§ ND§
[21.5-3650]
200 mg TID¶ (n=215) 583 (65) 15,900 (62) 51.2 (54) 2425 (39) 37.2 (39)
[89.7-2200] [4100-56,100] [10.7-146] [828-5702] [19.1-148]
400 mg BID# (n=23) 723 (86) 9093 (80) 76.1 (78) 3088 (84) 31.7 (42)
[6.70-2256] [1564-26,794] [14.9-256] [407-13,140] [12.4-67.3]
Cavg = the average posaconazole concentration when measured at steady state
* Oral suspension administration
†
AUC (0-24 hr) for 200 mg TID and AUC (0-12 hr) for 400 mg BID
‡
HSCT recipients with GVHD
§
Not done
¶
Neutropenic patients who were receiving cytotoxic chemotherapy for acute myelogenous leukemia or myelodysplastic
syndromes
#
Febrile neutropenic patients or patients with refractory invasive fungal infections, Cavg n=24
The variability in average plasma posaconazole concentrations in patients was relatively higher than that in healthy
subjects.
Absorption:
Posaconazole Delayed-Release Tablets
When given orally in healthy volunteers, posaconazole delayed-release tablets are absorbed with a
median Tmax of 4 to 5 hours. Steady-state plasma concentrations are attained by Day 6 at the 300 mg
dose (QD after BID loading dose at Day 1). The absolute bioavailability of the oral delayed-release tablet
is approximately 54% under fasted conditions. The Cmax and AUC of posaconazole following
administration of posaconazole delayed-release tablets is increased 16% and 51%, respectively, when
given with a high fat meal compared to a fasted state (see Table 17). In order to enhance the oral
absorption of posaconazole and optimize plasma concentrations, posaconazole delayed-release tablets
should be administered with food.
Table 17: Statistical Comparison of Plasma Pharmacokinetics of Posaconazole Following

Single Oral Dose Administration of 300 mg Posaconazole Delayed-Release Tablet to Healthy
Subjects under Fasting and Fed Conditions
Fed Conditions
Fasting Conditions Fed/Fasting
(High Fat Meal)*
Pharmacokinetic
N Mean (%CV) N Mean (%CV) GMR (90% CI)
Parameter
Cmax (ng/mL) 14 935 (34) 16 1060 (25) 1.16 (0.96, 1.41)
AUC0-72hr
14 26200 (28) 16 38400 (18) 1.51 (1.33, 1.72)
(hr∙ng/mL)
5.00 6.00
Tmax† (hr) 14 16 N/A
(3.00, 8.00) (5.00, 24.00)
GMR=Geometric least-squares mean ratio; CI=Confidence interval
* 48.5 g fat
†
Median (Min, Max) reported for Tmax
Concomitant administration of posaconazole delayed-release tablets with drugs affecting gastric pH or

gastric motility did not demonstrate any significant effects on posaconazole pharmacokinetic exposure
(see Table 18).
23

Table 18: The Effect of Concomitant Medications that Affect the Gastric pH and Gastric Motility on
the Pharmacokinetics of Posaconazole Delayed-Release Tablets in Healthy Volunteers
Change in Cmax Change in AUC0-last

(ratio estimate*; (ratio estimate*;
90% CI of the ratio 90% CI of the ratio
Coadministered Drug Administration Arms estimate) estimate)
↑6% ↑4%
Mylanta Ultimate strength liquid
25.4 meq/5 mL, 20 mL
(Increase in gastric pH)
(1.06; 0.90 -1.26)↑ (1.04; 0.90 -1.20)
Ranitidine (Zantac) (Alteration in 150 mg (morning dose of ↑4% ↓3%

gastric pH) 150 mg Ranitidine BID)
(1.04; 0.88 -1.23)↑ (0.97; 0.84 -1.12)
↑2% ↑5%
Esomeprazole (Nexium) (Increase 40 mg (QAM 5 days, day -4 to
in gastric pH) 1)
(1.02; 0.88-1.17)↑ (1.05; 0.89 -1.24)
↓14% ↓7%
Metoclopramide (Reglan) (Increase 15 mg four times daily during 2
in gastric motility) days (Day -1 and 1)
(0.86, 0.73,1.02) (0.93, 0.803,1.07)
* Ratio Estimate is the ratio of coadministered drug plus posaconazole to posaconazole alone for Cmax or AUC0-last.
Posaconazole Oral Suspension

Posaconazole oral suspension is absorbed with a median Tmax of ~3 to 5 hours. Steady-state plasma
concentrations are attained at 7 to 10 days following multiple-dose administration.
Following single-dose administration of 200 mg, the mean AUC and Cmax of posaconazole are
approximately 3-times higher when the oral suspension is administered with a nonfat meal and
approximately 4-times higher when administered with a high-fat meal (~50 gm fat) relative to the fasted
state. Following single-dose administration of posaconazole oral suspension 400 mg, the mean AUC and
Cmax of posaconazole are approximately 3-times higher when administered with a liquid nutritional
supplement (14 gm fat) relative to the fasted state (see Table 19). In addition, the effects of varying
gastric administration conditions on the Cmax and AUC of posaconazole oral suspension in healthy
volunteers have been investigated and are shown in Table 20.
In order to assure attainment of adequate plasma concentrations, it is recommended to administer
Noxafil oral suspension during or immediately following a full meal. In patients who cannot eat a full meal,
Noxafil oral suspension should be taken with a liquid nutritional supplement or an acidic carbonated
beverage (e.g., ginger ale).
Table 19: The Mean (%CV) [min-max] Posaconazole Pharmacokinetic Parameters Following
Single-Dose Oral Suspension Administration of 200 mg and 400 mg Under Fed and Fasted
Conditions
Cmax Tmax* AUC (I) CL/F t½

Dose (mg) (ng/mL) (hr) (ng·hr/mL) (L/hr) (hr)
200 mg fasted 132 (50) 3.50 4179 (31) 51 (25) 23.5 (25)
(n=20)† [45-267] [1.5-36‡] [2705-7269] [28-74] [15.3-33.7]
200 mg nonfat 378 (43) 10,753 (35) 21 (39) 22.2 (18)
(n=20)† [131-834] 4 [3-5] [4579-17,092] [12-44] [17.4-28.7]
200 mg high fat
512 (34) 15,059 (26) 14 (24) 23.0 (19)
(54 gm fat)
[241-1016] 5 [4-5] [10,341-24,476] [8.2-19] [17.2-33.4]
(n=20)†
400 mg fasted 121 (75) 5258 (48) 91 (40) 27.3 (26)
(n=23)§ [27-366] 4 [2-12] [2834-9567] [42-141] [16.8-38.9]
24

400 mg with liquid
nutritional supplement 355 (43) 11,295 (40) 43 (56) 26.0 (19)
(14 gm fat) [145-720] 5 [4-8] [3865-20,592] [19-103] [18.2-35.0]
(n=23)§
* Median [min-max].
†
n=15 for AUC (I), CL/F, and t ½
‡
The subject with Tmax of 36 hrs had relatively constant plasma levels over 36 hrs (1.7 ng/mL
difference between 4 hrs and 36 hrs).
§
n=10 for AUC (I), CL/F, and t ½
Table 20: The Effect of Varying Gastric Administration Conditions on the Cmax and AUC of
Posaconazole Oral Suspension in Healthy Volunteers*
Change in Cmax Change in AUC
(ratio estimate†; (ratio estimate†;
90% CI of the ratio 90% CI of the ratio
Study Description Administration Arms estimate) estimate)
↑96% ↑111%
5 minutes before high-fat meal
(1.96; 1.48-2.59) (2.11; 1.60-2.78)
400-mg single dose with a high-fat
↑339% ↑382%
meal relative to fasted state (n=12)
During high-fat meal
(4.39; 3.32-5.80) (4.82; 3.66-6.35)
↑333% ↑387%
20 minutes after high-fat meal
(4.33; 3.28-5.73) (4.87; 3.70-6.42)
400 mg BID and 200 mg QID for 7 ↑65% ↑66%

400 mg BID with BOOST
days in fasted state and with liquid
(1.65; 1.29-2.11) (1.66; 1.30-2.13)
nutritional supplement (BOOST®)
(n=12) 200 mg QID with BOOST No Effect No Effect
↑136% ↑161%
Divided daily dose from 400 mg BID Fasted state
(2.36; 1.84-3.02) (2.61; 2.04-3.35)
to 200 mg QID for 7 days regardless
of fasted conditions or with BOOST
↑137% ↑157%
(n=12) With BOOST
(2.37; 1.86-3.04) (2.57; 2.00-3.30)
↑92% ↑70%
400-mg single dose with carbonated Ginger ale
(1.92; 1.51-2.44) (1.70; 1.43-2.03)
acidic beverage (ginger ale) and/or
proton pump inhibitor
↓32% ↓30%
(esomeprazole) (n=12) Esomeprazole
(0.68; 0.53-0.86) (0.70; 0.59-0.83)
↓21% ↓19%
400-mg single dose with a prokinetic With metoclopramide + BOOST
agent (metoclopramide 10 mg TID (0.79; 0.72-0.87) (0.81; 0.72-0.91)
for 2 days) + BOOST or an
antikinetic agent (loperamide 4-mg ↓3% ↑11%
single dose) + BOOST (n=12) With loperamide + BOOST
(0.97; 0.88-1.07) (1.11; 0.99-1.25)
400-mg single dose either orally ↓19% ↓23%

with BOOST or via an NG tube with Via NG tube‡
BOOST (n=16) (0.81; 0.71-0.91) (0.77; 0.69-0.86)
* In 5 subjects, the Cmax and AUC decreased substantially (range: -27% to -53% and -33% to -51%, respectively) when
Noxafil was administered via an NG tube compared to when Noxafil was administered orally. It is recommended to closely
monitor patients for breakthrough fungal infections when Noxafil is administered via an NG tube because a lower plasma
exposure may be associated with an increased risk of treatment failure.
†
Ratio Estimate is the ratio of coadministered drug plus posaconazole to coadministered drug alone for Cmax or AUC.
‡
NG = nasogastric
25

Concomitant administration of posaconazole oral suspension with drugs affecting gastric pH or gastric
motility results in lower posaconazole exposure. (See Table 21.)
Table 21: The Effect of Concomitant Medications that Affect the Gastric pH and Gastric Motility on
the Pharmacokinetics of Posaconazole Oral Suspension in Healthy Volunteers
Effect on Bioavailability of Posaconazole

Change in Mean Change in Mean
Cmax AUC
Coadministered Drug
(Postulated (ratio estimate*; (ratio estimate*;
Mechanism of Coadministered Posaconazole 90% CI of the ratio 90% CI of the ratio
Interaction) Drug Dose/Schedule Dose/Schedule estimate) estimate)
Cimetidine 400 mg BID × 10 days 200 mg (tablets) QD ↓ 39% ↓ 39%
(Alteration of gastric × 10 days† (0.61; 0.53-0.70) (0.61; 0.54-0.69)
pH)
Esomeprazole 400 mg (oral
↓ 46% ↓ 32%
(Increase in gastric 40 mg QAM × 3 days suspension) single
‡ (0.54; 0.43-0.69) (0.68; 0.57-0.81)
pH) dose
Metoclopramide 400 mg (oral
↓ 21% ↓ 19%
(Increase in gastric 10 mg TID × 2 days suspension) single
‡ (0.79; 0.72-0.87) (0.81; 0.72-0.91)
motility) dose
* Ratio Estimate is the ratio of coadministered drug plus posaconazole to coadministered drug alone for Cmax or AUC.
†
The tablet refers to a non-commercial tablet formulation without polymer.
‡
The drug interactions associated with the oral suspension are also relevant for the delayed-release tablet with the exception
of Esomeprazole and Metoclopramide.
Distribution:
The mean volume of distribution of posaconazole after intravenous solution administration was 261 L
and ranged from 226-295 L between studies and dose levels.
Posaconazole is highly bound to human plasma proteins (>98%), predominantly to albumin.
Metabolism:
Posaconazole primarily circulates as the parent compound in plasma. Of the circulating metabolites,
the majority are glucuronide conjugates formed via UDP glucuronidation (phase 2 enzymes).
Posaconazole does not have any major circulating oxidative (CYP450 mediated) metabolites. The
excreted metabolites in urine and feces account for ~17% of the administered radiolabeled dose.
Posaconazole is primarily metabolized via UDP glucuronidation (phase 2 enzymes) and is a substrate
for p-glycoprotein (P-gp) efflux. Therefore, inhibitors or inducers of these clearance pathways may affect
posaconazole plasma concentrations. A summary of drugs studied clinically with the oral suspension or
an early tablet formulation, which affect posaconazole concentrations, is provided in Table 22.
Table 22: Summary of the Effect of Coadministered Drugs on Posaconazole in Healthy Volunteers
Effect on Bioavailability of Posaconazole

Change in Mean Change in Mean
Coadministered Drug Cmax AUC
(Postulated (ratio estimate*; 90% (ratio estimate*; 90%
Mechanism of Coadministered Posaconazole CI of the ratio CI of the ratio
Interaction) Drug Dose/Schedule Dose/Schedule estimate) estimate)
Efavirenz 400 mg QD × 10 and 400 mg (oral ↓45% ↓ 50%
(UDP-G Induction) 20 days suspension) BID × 10 (0.55; 0.47-0.66) (0.50; 0.43-0.60)
and 20 days
Fosamprenavir 700 mg BID x 10 days 200 mg QD on the 1st ↓21% ↓23%
(unknown mechanism) day, 200 mg BID on 0.79 (0.71-0.89) 0.77 (0.68-0.87)
the 2nd day, then 400
mg BID x 8 Days
26

Rifabutin 300 mg QD x 17 days 200 mg (tablets) QD ↓ 43% ↓ 49%
(UDP-G Induction) × 10 days† (0.57; 0.43-0.75) (0.51; 0.37-0.71)
Phenytoin 200 mg QD x 10 days 200 mg (tablets) QD ↓ 41% ↓ 50%
(UDP-G Induction) × 10 days† (0.59; 0.44-0.79) (0.50; 0.36-0.71)
* Ratio Estimate is the ratio of coadministered drug plus posaconazole to posaconazole alone for Cmax or AUC.
†
In vitro studies with human hepatic microsomes and clinical studies indicate that posaconazole is an
inhibitor primarily of CYP3A4. A clinical study in healthy volunteers also indicates that posaconazole is a
strong CYP3A4 inhibitor as evidenced by a >5-fold increase in midazolam AUC. Therefore, plasma
concentrations of drugs predominantly metabolized by CYP3A4 may be increased by posaconazole. A
summary of the drugs studied clinically, for which plasma concentrations were affected by posaconazole,
is provided in Table 23 [see Contraindications (4) and Drug Interactions (7.1) including
recommendations].
Table 23: Summary of the Effect of Posaconazole on Coadministered Drugs in Healthy Volunteers
and Patients
Effect on Bioavailability of
Coadministered Coadministered
Drug Drugs
(Postulated
Mechanism of Change in Mean
Interaction is Cmax
Inhibition of (ratio estimate*; Change in Mean AUC
CYP3A4 by Coadministered Drug Posaconazole Dose/ 90% CI of the ratio (ratio estimate*; 90%
posaconazole) Dose/Schedule Schedule estimate) CI of the ratio estimate)
Sirolimus 2-mg single oral dose 400 mg (oral suspension) ↑ 572% ↑ 788%
BID x 16 days (6.72; 5.62-8.03) (8.88; 7.26-10.9)
Cyclosporine Stable maintenance 200 mg (tablets) QD x 10
†
↑ cyclosporine whole blood trough
dose in heart transplant days concentrations
recipients Cyclosporine dose reductions of up to 29%
were required
Tacrolimus 0.05-mg/kg single oral 400 mg (oral suspension) ↑ 121% ↑ 358%
dose BID × 7 days (2.21; 2.01-2.42) (4.58; 4.03-5.19)
Simvastatin 40-mg single oral dose 100 mg (oral suspension) Simvastatin Simvastatin
QD x 13 days ↑ 841% ↑ 931%
(9.41, 7.13-12.44) (10.31, 8.40-12.67)
Simvastatin Acid Simvastatin Acid
↑ 817% ↑634%
(9.17, 7.36-11.43) (7.34, 5.82-9.25)
200 mg (oral suspension) Simvastatin Simvastatin

QD x 13 days
↑ 1041% ↑ 960%
(11.41, 7.99-16.29) (10.60, 8.63-13.02)
Simvastatin Acid Simvastatin Acid
↑851% ↑748%
(9.51, 8.15-11.10) (8.48, 7.04-10.23)
27

Midazolam 0.4-mg single 200 mg (oral suspension) ↑ 30% ↑ 362%
intravenous dose‡ BID x 7 days (1.3; 1.13-1.48) (4.62; 4.02-5.3)
0.4-mg single 400 mg (oral suspension) ↑62% ↑524%

intravenous dose‡ BID x 7 days (1.62; 1.41-1.86) (6.24; 5.43-7.16)
200 mg (oral suspension) ↑ 169% ↑ 470%

2-mg single oral dose‡ QD x 7 days (2.69; 2.46-2.93) (5.70; 4.82-6.74)
400 mg (oral suspension) ↑ 138% ↑ 397%

2-mg single oral dose‡ (2.38; 2.13-2.66) (4.97; 4.46-5.54)
BID x 7 days
Rifabutin 300 mg QD x 17 days 200 mg (tablets) QD × 10 ↑ 31% ↑ 72%

†
days (1.31; 1.10-1.57) (1.72;1.51-1.95)
Phenytoin 200 mg QD PO x 10 200 mg (tablets) QD x 10 ↑ 16% ↑ 16%
†
days days (1.16; 0.85-1.57) (1.16; 0.84-1.59)
Ritonavir 100 mg QD x 14 days 400 mg (oral suspension) ↑ 49% ↑ 80%
BID x 7 days (1.49; 1.04-2.15) (1.8;1.39-2.31)
Atazanavir 300 mg QD x 14 days 400 mg (oral suspension) ↑ 155% ↑ 268%
BID x 7 days (2.55; 1.89-3.45) (3.68; 2.89-4.70)
Atazanavir/
ritonavir boosted 300 mg/100 mg QD x 400 mg (oral suspension) ↑ 53% ↑ 146%
regimen 14 days BID x 7 days (1.53; 1.13-2.07) (2.46; 1.93-3.13)
* Ratio Estimate is the ratio of coadministered drug plus posaconazole to coadministered drug alone for Cmax or AUC.
†
‡
The mean terminal half-life of midazolam was increased from 3 hours to 7 to 11 hours during coadministration with
posaconazole.
Additional clinical studies demonstrated that no clinically significant effects on zidovudine, lamivudine,
indinavir, or caffeine were observed when administered with posaconazole 200 mg QD; therefore, no
dose adjustments are required for these coadministered drugs when coadministered with posaconazole
200 mg QD.
Excretion:
Following administration of Noxafil oral suspension, posaconazole is predominantly eliminated in the
feces (71% of the radiolabeled dose up to 120 hours) with the major component eliminated as parent
drug (66% of the radiolabeled dose). Renal clearance is a minor elimination pathway, with 13% of the
radiolabeled dose excreted in urine up to 120 hours (<0.2% of the radiolabeled dose is parent drug).
Posaconazole injection is eliminated with a mean terminal half-life (t½) of 27 hours and a total body
clearance (CL) of 7.3 L/h.
Posaconazole delayed-release tablet is eliminated with a mean half-life (t½) ranging between 26 to 31
hours.
Posaconazole oral suspension is eliminated with a mean half-life (t½) of 35 hours (range: 20
66 hours).
12.4 Microbiology
Mechanism of Action:
Posaconazole blocks the synthesis of ergosterol, a key component of the fungal cell membrane,
through the inhibition of cytochrome P-450 dependent enzyme lanosterol 14α-demethylase responsible
for the conversion of lanosterol to ergosterol in the fungal cell membrane. This results in an accumulation
of methylated sterol precursors and a depletion of ergosterol within the cell membrane thus weakening
the structure and function of the fungal cell membrane. This may be responsible for the antifungal activity
of posaconazole.
Activity in vitro:
Posaconazole has in vitro activity against Aspergillus fumigatus and Candida albicans, including
Candida albicans isolates from patients refractory to itraconazole or fluconazole or both drugs [see
Clinical Studies (14), Indications and Usage (1) and Dosage and Administration (2)]. However, correlation
between the results of susceptibility tests and clinical outcome has not been established. Posaconazole
interpretive criteria (breakpoints) have not been established for any fungus.
28

Drug Resistance:
Clinical isolates of Candida albicans and Candida glabrata with decreased susceptibility to
posaconazole were observed in oral swish samples taken during prophylaxis with posaconazole and
fluconazole, suggesting a potential for development of resistance. These isolates also showed reduced
susceptibility to other azoles, suggesting cross-resistance between azoles. The clinical significance of this
finding is not known.
13 NONCLINICAL TOXICOLOGY
13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility
No drug-related neoplasms were recorded in rats or mice treated with posaconazole for 2 years at
doses higher than the clinical dose. In a 2-year carcinogenicity study, rats were given posaconazole orally
at doses up to 20 mg/kg (females), or 30 mg/kg (males). These doses are equivalent to 3.9- or 3.5-times
the exposure achieved with a 400-mg BID oral suspension regimen, respectively, based on steady-state
AUC in healthy volunteers administered a high-fat meal (400-mg BID oral suspension regimen). In the
mouse study, mice were treated at oral doses up to 60 mg/kg/day or 4.8-times the exposure achieved
with a 400-mg BID oral suspension regimen.
Posaconazole was not genotoxic or clastogenic when evaluated in bacterial mutagenicity (Ames), a
chromosome aberration study in human peripheral blood lymphocytes, a Chinese hamster ovary cell
mutagenicity study, and a mouse bone marrow micronucleus study.
Posaconazole had no effect on fertility of male rats at a dose up to 180 mg/kg (1.7 x the 400-mg BID
oral suspension regimen based on steady-state plasma concentrations in healthy volunteers) or female
rats at a dose up to 45 mg/kg (2.2 x the 400-mg BID oral suspension regimen).
13.2 Animal Toxicology and/or Pharmacology
In a nonclinical study using intravenous administration of posaconazole in very young dogs (dosed
from 2 to 8 weeks of age), an increase in the incidence of brain ventricle enlargement was observed in
treated animals as compared with concurrent control animals. No difference in the incidence of brain
ventricle enlargement between control and treated animals was observed following the subsequent 5
month treatment-free period. There were no neurologic, behavioral or developmental abnormalities in the
dogs with this finding, and a similar brain finding was not seen with oral posaconazole administration to
juvenile dogs (4 days to 9 months of age).
The clinical significance of this finding is unknown; therefore, the use of posaconazole injection to
patients under 18 years of age is not recommended.
14 CLINICAL STUDIES
14.1 Prophylaxis of Aspergillus and Candida Infections with Posaconazole Oral Suspension
Two randomized, controlled studies were conducted using posaconazole as prophylaxis for the
prevention of invasive fungal infections (IFIs) among patients at high risk due to severely compromised
immune systems.
The first study (Oral Suspension Study 1) was a randomized, double-blind trial that compared
posaconazole oral suspension (200 mg three times a day) with fluconazole capsules (400 mg once daily)
as prophylaxis against invasive fungal infections in allogeneic hematopoietic stem cell transplant (HSCT)
recipients with Graft versus Host Disease (GVHD). Efficacy of prophylaxis was evaluated using a
composite endpoint of proven/probable IFIs, death, or treatment with systemic antifungal therapy
(patients may have met more than one of these criteria). This assessed all patients while on study
therapy plus 7 days and at 16 weeks post-randomization. The mean duration of therapy was comparable
between the 2 treatment groups (80 days, posaconazole; 77 days, fluconazole). Table 24 contains the
results from Oral Suspension Study 1.
Table 24: Results from Blinded Clinical Study in Prophylaxis of IFI in All Randomized Patients with
Hematopoietic Stem Cell Transplant (HSCT) and Graft-vs.-Host Disease (GVHD):
n=301 n=299
On therapy plus 7 days
29

Clinical Failure* 50 (17%) 55 (18%)
Failure due to:
Proven/Probable IFI 7 (2%) 22 (7%)
(Aspergillus) 3 (1%) 17 (6%)
(Candida) 1 (<1%) 3 (1%)
(Other) 3 (1%) 2 (1%)
All Deaths 22 (7%) 24 (8%)
Proven/probable fungal 2 (<1%) 6 (2%)
infection prior to death
†
SAF 27 (9%) 25 (8%)
Through 16 weeks
Clinical Failure*,‡ 99 (33%) 110 (37%)
Failure due to:
(Aspergillus) 7 (2%) 21 (7%)
(Candida) 4 (1%) 4 (1%)
(Other) 5 (2%) 2 (1%)
All Deaths 58 (19%) 59 (20%)
Proven/probable fungal 10 (3%) 16 (5%)
SAF† 26 (9%) 30 (10%)
Event free lost to follow-up§ 24 (8%) 30 (10%)
* Patients may have met more than one criterion defining failure.
†
Use of systemic antifungal therapy (SAF) criterion is based on protocol
definitions (empiric/IFI usage >4 consecutive days).
‡
95% confidence interval (posaconazole-fluconazole) = (-11.5%, +3.7%).
§
Patients who are lost to follow-up (not observed for 112 days), and who did
not meet another clinical failure endpoint. These patients were considered
failures.
The second study (Oral Suspension Study 2) was a randomized, open-label study that compared
posaconazole oral suspension (200 mg 3 times a day) with fluconazole suspension (400 mg once daily)
or itraconazole oral solution (200 mg twice a day) as prophylaxis against IFIs in neutropenic patients who
were receiving cytotoxic chemotherapy for AML or MDS. As in Oral Suspension Study 1, efficacy of
prophylaxis was evaluated using a composite endpoint of proven/probable IFIs, death, or treatment with
systemic antifungal therapy (Patients might have met more than one of these criteria). This study
assessed patients while on treatment plus 7 days and 100 days postrandomization. The mean duration of
therapy was comparable between the 2 treatment groups (29 days, posaconazole; 25 days, fluconazole
or itraconazole). Table 25 contains the results from Oral Suspension Study 2.
Table 25: Results from Open-Label Clinical Study 2 in Prophylaxis of IFI in All Randomized
Patients with Hematologic Malignancy and Prolonged Neutropenia:
Posaconazole Fluconazole/Itraconazole
n=304 n=298
On therapy plus 7 days
Clinical Failure*,† 82 (27%) 126 (42%)
Failure due to:
(Aspergillus) 2 (1%) 20 (7%)
(Candida) 3 (1%) 2 (1%)
(Other) 2 (1%) 3 (1%)
All Deaths 17 (6%) 25 (8%)
Proven/probable fungal 1 (<1%) 2 (1%)
SAF‡ 67 (22%) 98 (33%)
Through 100 days postrandomization

Clinical Failure† 158 (52%) 191 (64%)
Failure due to:
(Aspergillus) 2 (1%) 26 (9%)
30

(Candida) 10 (3%) 4 (1%)
(Other) 2 (1%) 3 (1%)
All Deaths 44 (14%) 64 (21%)
Proven/probable fungal 2 (1%) 16 (5%)
SAF‡ 98 (32%) 125 (42%)
Event free lost to follow-up§ 34 (11%) 24 (8%)
* 95% confidence interval (posaconazole-fluconazole/itraconazole) = (-22.9%, -7.8%).
†
Patients may have met more than one criterion defining failure.
‡
Use of systemic antifungal therapy (SAF) criterion is based on protocol definitions (empiric/IFI
usage >3 consecutive days).
§
Patients who are lost to follow-up (not observed for 100 days), and who did not meet another
clinical failure endpoint. These patients were considered failures.
In summary, 2 clinical studies of prophylaxis were conducted with the posaconazole oral suspension.
As seen in the accompanying tables (Tables 24 and 25), clinical failure represented a composite
endpoint of breakthrough IFI, mortality and use of systemic antifungal therapy. In Oral Suspension Study
1 (Table 24), the clinical failure rate of posaconazole (33%) was similar to fluconazole (37%), (95% CI for
the difference posaconazole–comparator -11.5% to 3.7%) while in Oral Suspension Study 2 (Table 25)
clinical failure was lower for patients treated with posaconazole (27%) when compared to patients treated
with fluconazole or itraconazole (42%), (95% CI for the difference posaconazole–comparator -22.9% to
7.8%).
All-cause mortality was similar at 16 weeks for both treatment arms in Oral Suspension Study 1 [POS
58/301 (19%) vs. FLU 59/299 (20%)]; all-cause mortality was lower at 100 days for posaconazole-treated
patients in Oral Suspension Study 2 [POS 44/304 (14%) vs. FLU/ITZ 64/298 (21%)]. Both studies
demonstrated substantially fewer breakthrough infections caused by Aspergillus species in patients
receiving posaconazole prophylaxis when compared to patients receiving fluconazole or itraconazole.
14.2 Treatment of Oropharyngeal Candidiasis with Posaconazole Oral Suspension
Posaconazole Oral Suspension Study 3 was a randomized, controlled, evaluator-blinded study in HIV-
infected patients with oropharyngeal candidiasis. Patients were treated with posaconazole or fluconazole
oral suspension (both posaconazole and fluconazole were given as follows: 100 mg twice a day for 1 day
followed by 100 mg once a day for 13 days).
Clinical and mycological outcomes were assessed after 14 days of treatment and at 4 weeks after the
end of treatment. Patients who received at least 1 dose of study medication and had a positive oral swish
culture of Candida species at baseline were included in the analyses (see Table 26). The majority of the
subjects had C. albicans as the baseline pathogen.
Clinical success at Day 14 (complete or partial resolution of all ulcers and/or plaques and symptoms)
and clinical relapse rates (recurrence of signs or symptoms after initial cure or improvement) 4 weeks
after the end of treatment were similar between the treatment arms (see Table 26).
Mycologic eradication rates (absence of colony forming units in quantitative culture at the end of
therapy, Day 14), as well as mycologic relapse rates (4 weeks after the end of treatment) were also
similar between the treatment arms (see Table 26).
Table 26: Posaconazole Oral Suspension Clinical Success, Mycological Eradication, and Relapse
Rates in Oropharyngeal Candidiasis
Clinical Success at End of Therapy (Day 14) 155/169 (91.7%) 148/160 (92.5%)
Clinical Relapse (4 Weeks after End of Therapy) 45/155 (29.0%) 52/148 (35.1%)
Mycological Eradication (absence of CFU) at End of Therapy (Day 14) 88/169 (52.1%) 80/160 (50.0%)
Mycological Relapse (4 Weeks after End of Treatment) 49/88 (55.6%) 51/80 (63.7%)
Mycologic response rates, using a criterion for success as a posttreatment quantitative culture with
≤20 colony forming units (CFU/mL) were also similar between the two groups (posaconazole 68.0%,
fluconazole 68.1%). The clinical significance of this finding is unknown.
31

14.3 Posaconazole Oral Suspension Treatment of Oropharyngeal Candidiasis Refractory to
Treatment with Fluconazole or Itraconazole
Posaconazole Oral Suspension Study 4 was a noncomparative study of posaconazole oral
suspension in HIV-infected subjects with OPC that was refractory to treatment with fluconazole or
itraconazole. An episode of OPC was considered refractory if there was failure to improve or worsening of
OPC after a standard course of therapy with fluconazole greater than or equal to 100 mg/day for at least
10 consecutive days or itraconazole 200 mg/day for at least 10 consecutive days and treatment with
either fluconazole or itraconazole had not been discontinued for more than 14 days prior to treatment with
posaconazole. Of the 199 subjects enrolled in this study, 89 subjects met these strict criteria for refractory
infection.
Forty-five subjects with refractory OPC were treated with posaconazole oral suspension 400 mg BID
for 3 days, followed by 400 mg QD for 25 days with an option for further treatment during a 3-month
maintenance period. Following a dosing amendment, a further 44 subjects were treated with
posaconazole 400 mg BID for 28 days. The efficacy of posaconazole was assessed by the clinical
success (cure or improvement) rate after 4 weeks of treatment. The clinical success rate was 74.2%
(66/89). The clinical success rates for both the original and the amended dosing regimens were similar
(73.3% and 75.0%, respectively).
16 HOW SUPPLIED/STORAGE AND HANDLING

Injection
Noxafil injection is available in Type I glass vials closed with bromobutyl rubber stopper and aluminum
seal (NDC 0085-4331-01) containing 300 mg per 16.7 mL of solution (18 mg of posaconazole per mL).
Store refrigerated at 2-8°C (36-46°F).
Delayed-Release Tablets
Noxafil 100 mg delayed-release tablets; yellow, coated, oblong, debossed with "100" on one side.
Bottles with child-resistant closures of 60 delayed-release tablets (NDC 0085-4324-02). Store at 20-25°C
(68-77°F), excursions permitted to 15-30°C (59-86°F) [see USP Controlled Room Temperature].
Oral Suspension
Noxafil oral suspension is available in 4-ounce (123 mL) amber glass bottles with child-resistant
closures (NDC 0085-1328-01) containing 105 mL of suspension (40 mg of posaconazole per mL).
Supplied with each oral suspension bottle is a plastic dosing spoon calibrated for measuring
2.5-mL and 5-mL doses. Store at 25°C (77°F); excursions permitted to 15-30°C (59-86°F) [see USP
Controlled Room Temperature]. DO NOT FREEZE.
17 PATIENT COUNSELING INFORMATION

Advise the patient to read the FDA-approved patient labeling (Patient Information).
17.1 Administration
Noxafil Delayed-Release Tablets
Advise patients to take Noxafil delayed-release tablets with food.
Advise patients that Noxafil delayed-release tablets must be swallowed whole and not divided,
crushed, or chewed.
Instruct patients that if they miss a dose, they should take it as soon as they remember. If they do not
remember until it is within 12 hours of the next dose, they should be instructed to skip the missed dose
and go back to the regular schedule. Patients should not double their next dose or take more than the
prescribed dose.
Noxafil Oral Suspension
Advise patients to take each dose of Noxafil oral suspension during or immediately (i.e., within 20
minutes) following a full meal. In patients who cannot eat a full meal, each dose of Noxafil oral
suspension should be administered with a liquid nutritional supplement or an acidic carbonated beverage
(e.g., ginger ale) in order to enhance absorption.
32

Instruct patients that if they miss a dose, they should take it as soon as they remember. However, if it
is almost time for the next dose, they should be instructed to skip the missed dose and go back to the
regular schedule. Patients should not double their next dose or take more than the prescribed dose.
17.2 Drug Interactions
Advise patients to inform their physician immediately if they:
• develop severe diarrhea or vomiting.
• are currently taking drugs that are known to prolong the QTc interval and are metabolized through
CYP3A4.
• are currently taking a cyclosporine or tacrolimus, or they notice swelling in an arm or leg or
shortness of breath.
• are taking other drugs or before they begin taking other drugs as certain drugs can decrease or
increase the plasma concentrations of posaconazole.
17.3 Serious and Potentially Serious Adverse Reactions
Advise patients to inform their physician immediately if they:
• notice a change in heart rate or heart rhythm, or have a heart condition or circulatory disease.
Posaconazole can be administered with caution to patients with potentially proarrhythmic
conditions.
• are pregnant, plan to become pregnant, or are nursing.
• have liver disease or develop itching, nausea or vomiting, their eyes or skin turn yellow, they feel
more tired than usual or feel like they have the flu.
• have ever had an allergic reaction to other antifungal medicines such as ketoconazole,
fluconazole, itraconazole, or voriconazole.
Injection: Manuf. by: Schering-Plough (Brinny) Co., Brinny, Innishannon, County Cork, Ireland
Delayed-Release Tablets: Manuf. by: N. V. Organon, Kloosterstraat 6, 5349 AB Oss, Netherlands
Oral Suspension: Manuf. by: Patheon Inc., Whitby, Ontario, Canada L1N 5Z5
For patent information: www.merck.com/product/patent/home.html
The trademarks referenced herein are owned by their respective companies.
Copyright © 2006, 2010, 2013, 2014 Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
All rights reserved.
uspi-mk5592-mf-1511r035
33

Patient Information
®
Noxafil (NOX-a-fil)
(posaconazole) injection
®
Noxafil (NOX-a-fil)
(posaconazole) delayed-release tablets
®
Noxafil (NOX-a-fil)
(posaconazole) oral suspension
What is Noxafil?
Noxafil injection, delayed-release tablets, and oral suspension are prescription medicines used to help prevent fungal
infections that can spread throughout your body (invasive fungal infections). These infections are caused by fungi called
Aspergillus or Candida. Noxafil is used in people who have an increased chance of getting these infections due to a weak
immune system. These include people who have:
• had a hematopoietic stem cell transplantation (bone marrow transplant) with graft versus host disease
• a low white blood cell count due to chemotherapy for blood cancers (hematologic malignancy)
Noxafil oral suspension is also used to treat a fungal infection called “thrush” caused by Candida in your mouth or throat
area. Noxafil oral suspension can be used as the first treatment for thrush, or as another treatment for thrush after
itraconazole or fluconazole treatment has not worked.
Noxafil injection is for adults over 18 years of age. It is not known if Noxafil injection is safe and effective in children under
18 years of age.
Noxafil delayed-release tablets and oral suspension are for adults and children over 13 years of age.
It is not known if Noxafil oral suspension and delayed-release tablets are safe and effective in children under 13 years of
age.
Who should not take Noxafil?
Do not take Noxafil if you:
• are allergic to posaconazole, any of the ingredients in Noxafil, or other azole antifungal medicines. See the end of
this leaflet for a complete list of ingredients in Noxafil.
• are taking any of the following medicines:
o sirolimus
o pimozide
o quinidine
o certain statin medicines that lower cholesterol (atorvastatin, lovastatin, simvastatin)
o ergot alkaloids (ergotamine, dihydroergotamine)
Ask your healthcare provider or pharmacist if you are not sure if you are taking any of these medicines.
Do not start taking a new medicine without talking to your healthcare provider or pharmacist.
What should I tell my healthcare provider before taking Noxafil?
Before you take Noxafil, tell your healthcare provider if you:
• are taking certain medicines that lower your immune system like cyclosporine or tacrolimus.
• are taking certain drugs for HIV infection, such as ritonavir, atazanavir, efavirenz, or fosamprenavir. Efavirenz and
fosamprenavir can cause a decrease in the Noxafil levels in your body. Efavirenz and fosamprenavir should not be
taken with Noxafil.
• are taking midazolam, a hypnotic and sedative medicine.
• have or had liver problems.
• have or had kidney problems.
• have or had an abnormal heart rate or rhythm, heart problems, or blood circulation problems.
• are pregnant or plan to become pregnant. It is not known if Noxafil will harm your unborn baby.
• are breastfeeding or plan to breastfeed. It is not known if Noxafil passes into your breast milk. You and your
34

healthcare provider should decide if you will take Noxafil or breastfeed. You should not do both.
Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines,
vitamins, and herbal supplements. Noxafil can affect the way other medicines work, and other medicines can affect the
way Noxafil works, and can cause serious side effects.
Especially tell your healthcare provider if you take:
• rifabutin or phenytoin. If you are taking these medicines, you should not take Noxafil delayed-release tablets or Noxafil
oral suspension.
• cimetidine or esomeprazole. If you are taking these medicines, you should not take Noxafil oral suspension.
Ask your healthcare provider or pharmacist for a list of these medicines if you are not sure.
Know the medicines you take. Keep a list of them with you to show your healthcare provider or pharmacist when you get a
new medicine.
How will I take Noxafil?
• Do not switch between taking Noxafil delayed-release tablets and Noxafil oral suspension without talking to your
healthcare provider.
• Take Noxafil exactly as your healthcare provider tells you to take it.
• Your healthcare provider will tell you how much Noxafil to take and when to take it.
• Take Noxafil for as long as your healthcare provider tells you to take it.
• If you take too much Noxafil, call your healthcare provider or go to the nearest hospital emergency room right away.
• Noxafil injection is usually given over 30 to 90 minutes through a plastic tube placed in your vein.
• Noxafil delayed-release tablets:
o Take Noxafil delayed-release tablets with food.
o Take Noxafil delayed-release tablets whole. Do not break, crush, or chew Noxafil delayed-release tablets before
swallowing. If you cannot swallow Noxafil delayed-release tablets whole, tell your healthcare provider. You may
need a different medicine.
o If you miss a dose, take it as soon as you remember and then take your next scheduled dose at its regular time. If
it is within 12 hours of your next dose, do not take the missed dose. Skip the missed dose and go back to your
regular schedule. Do not double your next dose or take more than your prescribed dose.
• Noxafil oral suspension:
o Shake Noxafil oral suspension well before use.
o Take each dose of Noxafil oral suspension during or within 20 minutes after a full meal. If you cannot eat a full
meal, take each dose of Noxafil oral suspension with a liquid nutritional supplement or an acidic carbonated
beverage, like ginger ale.
o A measured dosing spoon comes with your Noxafil oral suspension and is marked for doses of 2.5 mL and 5 mL.
See Figure A.
Figure A
o Rinse the spoon with water after each dose of Noxafil oral suspension and before you store it away.
o If you miss a dose, take it as soon as you remember. However, if it is almost time for the next dose, skip
the missed dose and go back to the regular dosing schedule. Do not take a double dose to make up for
the forgotten dose.
Follow the instructions from your healthcare provider on how much Noxafil you should take and when to take it.
What are the possible side effects of Noxafil?
Noxafil may cause serious side effects, including:
35

• drug interactions with cyclosporine or tacrolimus. If you take Noxafil with cyclosporine or tacrolimus, your blood
levels of cyclosporine or tacrolimus may increase. Serious side effects can happen in your kidney or brain if you have
high levels of cyclosporine or tacrolimus in your blood. Your healthcare provider should do blood tests to check your
levels of cyclosporine or tacrolimus if you are taking these medicines while taking Noxafil. Tell your healthcare
provider right away if you have swelling in your arm or leg or shortness of breath.
• problems with the electrical system of your heart (arrhythmias and QTc prolongation). Certain medicines used
to treat fungus called azoles, including posaconazole, the active ingredient in Noxafil, may cause heart rhythm
problems. People who have certain heart problems or who take certain medicines have a higher chance for this
problem. Tell your healthcare provider right away if your heartbeat becomes fast or irregular.
• liver problems. Some people who also have other serious medical problems may have severe liver problems that
may lead to death, especially if you take certain doses of Noxafil. Your healthcare provider should do blood tests to
check your liver while you are taking Noxafil. Call your healthcare provider right away if you have any of the following
symptoms of liver problems:
o itchy skin o feeling very tired
o nausea or vomiting o flu-like symptoms
o yellowing of your eyes
• increased amounts of midazolam in your blood. If you take Noxafil with midazolam, Noxafil increases the amount
of midazolam in your blood. This can make your sleepiness last longer. Your healthcare provider should check you
closely for side effects if you take midazolam with Noxafil.
The most common side effects of Noxafil include:
• diarrhea • headache
• nausea • coughing
• fever • low potassium levels in the blood
• vomiting
If you take Noxafil delayed-release tablets or Noxafil oral suspension, tell your healthcare provider right away if you have
diarrhea or vomiting.
Tell your healthcare provider if you have any side effect that bothers you or that does not go away.
These are not all the possible side effects of Noxafil. For more information, ask your healthcare provider or pharmacist.
Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
How should I store Noxafil?
•
Store Noxafil injection refrigerated at 36°F to 46°F (2°C to 8°C).
•
Store Noxafil delayed-release tablets and oral suspension at room temperature between 68°F to 77°F (20°C to
25°C).
• Do not freeze Noxafil oral suspension.
• Safely throw away medicine that is out of date or no longer needed.
Keep Noxafil and all medicines out of the reach of children.
General information about the safe and effective use of Noxafil.
Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. Do not use
Noxafil for a condition for which it was not prescribed. Do not give Noxafil to other people, even if they have the same
symptoms that you have. It may harm them. You can ask your pharmacist or healthcare provider for information about
Noxafil that is written for health professionals.
What are the ingredients in Noxafil?
Active ingredient: posaconazole
Inactive ingredients:
Noxafil injection: Betadex Sulfobutyl Ether Sodium (SBECD), edetate sodium, hydrochloric acid, sodium hydroxide, and
water for injection.
36

Noxafil delayed-release tablets: hypromellose acetate succinate, microcrystalline cellulose, hydroxypropylcellulose,
silicon dioxide, croscarmellose sodium, magnesium stearate, and Opadry® II Yellow (consists of the following
ingredients: polyvinyl alcohol partially hydrolyzed, Macrogol/PEG 3350, titanium dioxide, talc, and iron oxide yellow)
Noxafil oral suspension: polysorbate 80, simethicone, sodium benzoate, sodium citrate dihydrate, citric acid
monohydrate, glycerin, xanthan gum, liquid glucose, titanium dioxide, artificial cherry flavor, and purified water
Injection: Schering-Plough (Brinny) Co., Innishannon, County Cork, Ireland

Delayed-Release Tablets: Manuf. by: N. V. Organon, Kloosterstraat 6, 5349 AB Oss, Netherlands
Oral Suspension: Manuf. by: Patheon Inc., Whitby, Ontario, Canada L1N 5Z5
For patent information: www.merck.com/product/patent/home.html
The trademarks depicted in this piece are owned by their respective companies.
Copyright © 2006, 2010, 2013, 2014 Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
All rights reserved.
usppi-mk5592-mf-1511r015
For more information, go to www.noxafil.com or call 1-800-672-6372.
This Patient Informa ion has been approved by the U.S. Food and Drug Administration. Revised: 11/2015
37

(b) (4)
(b) (4) 
 

 


 

 



 
  
 

 
 
 


  
    
   
   
   
     
                                 
               
          
                       
             
         
                       
        
  
       
           

                 
                
 
          
 


 

(b) (4)
  
       
   
     
 
  
           
           
 
       

Reference ID: 3847805: Interaction

Uploaded by

Copyright:

Available Formats

Reference ID: 3847805: Interaction

Uploaded by

Document Information

Original Title

Copyright

Available Formats

Share this document

Share or Embed Document

Sharing Options

Did you find this document useful?

Is this content inappropriate?

Copyright:

Available Formats

Reference ID: 3847805: Interaction

Uploaded by

Copyright:

Available Formats

HIGHLIGHTS OF PRESCRIBING INFORMATION •

Noxafil oral suspension 40 mg per mL (3)

Reference ID: 3847805

Metabolized Through CYP3A4

FULL PRESCRIBING INFORMATION

1 INDICATIONS AND USAGE

1.2 Treatment of Oropharyngeal Candidiasis Including Oropharyngeal Candidiasis Refractory

Reference ID: 3847805

Noxafil delayed-release tablets and Noxafil oral suspension

2.2 Dosage, Preparation, Intravenous Line Compatibility and Administration of Noxafil

Table 1: Dosage for Noxafil Injection

• Equilibrate the refrigerated vial of Noxafil (posaconazole) injection to room temperature.

Reference ID: 3847805

Intravenous Line Compatibility:

Table 2: Compatible Diluents

Table 3: Compatible Drugs

Reference ID: 3847805

Lactated Ringer’s solution

• Noxafil injection must be administered through a 0.22 micron polyethersulfone (PES) or

2.3 Dosage and Administration Instructions for Noxafil Delayed-Release Tablets

Table 4: Dosage for Noxafil Delayed-Release Tablets

Maintenance dose: 300 mg (three 100 mg delayed-release tablets)

Administration Instructions for Noxafil Delayed-Release Tablets:

• Swallow tablets whole. Do not divide, crush, or chew.

2.4 Dosage and Administration Instructions for Noxafil Oral Suspension

Table 5: Dosage for Noxafil Oral Suspension

Reference ID: 3847805

Maintenance dose: 100 mg (2.5 mL) once a day for 13 days.

Administration Instructions for Noxafil Oral Suspension:

2.5 Non-Interchangeability between Noxafil Delayed-Release Tablets and Noxafil Oral

2.6 Dosage Adjustments in Patients with Renal Impairment

Reference ID: 3847805

5 WARNINGS AND PRECAUTIONS

Reference ID: 3847805

Reference ID: 3847805

Subjects Reporting any Adverse Reaction 220 (93) 235 (99)

Blood and Lymphatic System Disorder

Anemia 16 (7) 23 (10)

Thrombocytopenia 17 (7) 25 (11)

Abdominal Pain Upper 15 (6) 25 (11)

Abdominal Pain 30 (13) 41 (17)

Constipation 18 (8) 31 (13)

Diarrhea 75 (32) 93 (39)

Nausea 46 (19) 70 (30)

Vomiting 29 (12) 45 (19)

General Disorders and Administration Site Conditions

Fatigue 19 (8) 24 (10)

Chills 28 (12) 38 (16)

Edema Peripheral 28 (12) 35 (15)

Pyrexia 49 (21) 73 (31)

Metabolism and Nutrition Disorders

Decreased appetite 23 (10) 29 (12)

Hypokalemia 51 (22) 67 (28)

Hypomagnesemia 25 (11) 30 (13)

Reference ID: 3847805

Headache 33 (14) 49 (21)

Respiratory, Thoracic and Mediastinal Disorders

Cough 21 (9) 31 (13)

Dyspnea 16 (7) 24 (10)